The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

5-2019

Cross-presentation Is A Source of Tumor Antigens For Multiple
Myeloma Immunotherapy
Alexander A. Perakis

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Biology Commons, Cancer Biology Commons, Immunology and Infectious Disease
Commons, and the Medicine and Health Sciences Commons

Recommended Citation
Perakis, Alexander A., "Cross-presentation Is A Source of Tumor Antigens For Multiple Myeloma
Immunotherapy" (2019). The University of Texas MD Anderson Cancer Center UTHealth Graduate School
of Biomedical Sciences Dissertations and Theses (Open Access). 949.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/949

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

Cross-presentation Is A Source of Tumor Antigens For
Multiple Myeloma Immunotherapy
By
Alexander A. Perakis, B.A.
APPROVED:
__________________________
Gheath Al-Atrash, D.O., Ph.D., Advisory Professor
__________________________
Jeffrey J. Molldrem, M.D., Advisory Professor
__________________________
Michelle C. Barton, Ph.D.
__________________________
Michael A. Curran, Ph.D.
__________________________
Gregory A. Lizee, Ph.D.
__________________________
Stephanie S. Watowich, Ph.D.

APPROVED:
__________________________
Dean, The University of Texas
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences

Cross-presentation Is A Source of Tumor Antigens For
Multiple Myeloma Immunotherapy

A
DISSERTATION

Presented to the Faculty of
The University of Texas
MD Anderson Cancer Center UTHealth
Graduate School of Biomedical Sciences
In Partial Fulfillment
Of the Requirements
For the Degree of
DOCTOR OF PHILOSOPHY
By
Alexander A. Perakis, B.A.
Houston, Texas
May 2019

ii

Copyright
The American Association of Cancer Research (AACR) Journals permits
authors to reuse their article or parts of their articles in several ways including “in
support of a doctoral thesis or dissertation.” The full list of copyrights and
permissions granted to authors who publish in AACR journals can be found at
the following web address:
http://aacrjournals.org/content/authors/copyright-permissions-and-access

iii

Dedication
This work is dedicated to my loving family: My father, Alexander George Perakis,
my mother, Patty Perakis, and my sister, Olivia Perakis. Thank you for always
loving and supporting me through life. This work is as much mine as it is yours.

I would also like to dedicate this work to my loving friend, Clair Emily Bergeson. I
miss you every day. Thank you for bringing so much joy into my life in such a
short time and reminding me of the importance of cancer research.

iv

Acknowledgements
I would first like to thank my wonderful mentors Dr. Gheath Al-Atrash and
Dr. Jeffrey Molldrem. I have been very fortunate to have two mentors that have
taught and guided me through graduate school. Thank you Dr. Al-Atrash for
everything. You have been an amazing mentor, teacher, and friend. You have
taught me so much beyond science. Thank you for always being there for me
during these past six years. Thank you Dr. Molldrem for your endless support
during graduate school. You always challenged me to know what I know and
know what I don’t know. I am forever grateful for the wonderful lab you
established and let me call home during the past six years.

To my entire lab, you have become my second family. Dr. Celine Kerros,
thank you for being nothing short of a big sister to me. Thank you for teaching me
accountability, how to trouble shoot the (pardon my French) B.S. in experiments.
Thank you for being a shoulder to cry on during the hard times and someone to
share laughs with during the good ones. You are a friend for life. Dr. Anne
Philips, thank you for all your friendship and mentorship. You have taught me so
much and I would not be the scientist I am today without you. Thank you for
always willing to talk politics and nerd pop culture with me. Dr. Lisa St. John,
thank you for all you do keeping our lab above water. Thank you for being a
wonderful friend and lifeline for me. You always made me feel at home. Thank
you to Pariya Sukhumalchandra and Mao Zhang for all the hard work and effort
you put forth in training and helping me with so many experiments.
v

To my advisory committee, Drs. Michael Curran, Gregory Lizee,
Stephanie Watowich and Dean Michelle Barton, thank you for all your wisdom
and advice throughout the years. You all have shaped me to be the best student
and scientist and I am so appreciative of all the time you have invested in my
education. To Dean Barton, thank you for all the leadership opportunities you
provided be at GSBS. I am continually honored that you believed in me to serve
on so many wonderful committees and councils.

To my GSBS friends, thank you all for your friendship and companionship
throughout graduate school. It has been a wonderful journey to embark on with
all of you. To Erin Atkinson, we started together from the very beginning. You are
a friend for life, thank you for filling the years of graduate school with laughs.
Chris Evans, thank you for being such a great friend and roommate. To my fellow
Graduate Student Association queens, Jill Losh, Kimiya Young and Aundrietta
Duncan-thank you for making GSA one of the highlights of graduate school for
me. I am so grateful for all of your friendships and the wonderful memories we
had together.

Thank you Seth Freeman for reminding me of life outside the lab and for
helping me find my way through life. To all my friends back home, Dillon Peters,
Tara Peters, Lisa Greene, Justin Gunesch, Tyler Jacobson, thank you for your
unconditional love and support throughout life. To Eric Yoon, thank you from the

vi

bottom of my heart. You have been a wonderful partner. Thank you for all of your
unconditional love and support and always lifting me up.

To my incredible family, thank you for always believing in me. Thank you
to my loving parents for allowing me to chase my dreams. No matter what
obstacles were in front of me, you both were always willing to help get me there.
Thank you for all the sacrifices you have made to help Olivia and I be successful.
To my best friend in the world and sister, Olivia, thank you for always supporting
me. You are an inspiration to me and have always motivated me to be the best
version of myself. I am so fortunate to have you by my side to go through life.

vii

Abstract
CROSS-PRESENTATION IS A SOURCE OF TUMOR ANTIGENS FOR
MULTIPLE MYELOMA IMMUNOTHERAPY

Alexander A. Perakis, B.A.
Advisory Professors: Gheath Al-Atrash, D.O., Ph.D., Jeffrey J. Molldrem, MD.

Cross-presentation is an essential bridge between the innate and adaptive
arms of the immune system where antigen presenting cells (APCs) prime
cytotoxic T cell responses. We have recently identified cross-presentation as a
mechanism by which solid tumors present exogenous antigens. We therefore
hypothesized that multiple myeloma would be capable of cross-presentation as
these cells are derived from B cells, known APCs. We explored the capacity of
multiple myeloma to cross-present PR1, a human leukocyte antigen (HLA)-A2
nonameric peptide that is derived from neutrophil elastase (NE) and proteinase 3
(P3), and the ability to treat multiple myeloma using PR1-targeting
immunotherapies. Here we demonstrate that multiple myeloma cells lack
endogenous NE and P3 expression, possess the ability to take up exogenous NE
and P3 and cross-present PR1. This process employs the cytosolic antigen
presentation machinery including the proteasome, Golgi, and TAP. Subsequent
PR1 cross-presentation renders multiple myeloma cells susceptible to PR1-CTL
and anti-PR1/HLA-A2 antibody, both in vitro and in vivo. To our knowledge, this
is the first report of multiple myeloma cross-presenting tumor antigens.

viii

Collectively, our data demonstrate that PR1 is a novel tumor antigen in multiple
myeloma and can be effectively targeted using PR1-targeting immunotherapies.
Our study suggests that the multiple myeloma antigen repertoire is much larger
than previously appreciated, and that there is a new catalogue of potential
immunotherapeutic targets in multiple myeloma that can be derived from
exogenous antigens.
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Chapter 1: Introduction
1.1 The biology of multiple myeloma
The evolution of multiple myeloma
Multiple myeloma is characterized by the proliferation of clonal plasma
cells in the bone marrow. Normal plasma cells are terminally differentiated B
cells, dedicated to the production and secretion of antibodies integral to the
humoral response.1 Throughout B cell development, these cells undergo frequent
error-prone genetic processes, such as VDJ recombination, somatic
hypermutation, and Ig heavy chain (IgH) class switching, in order to generate
high avidity antibodies. These genetic modification events are prime
opportunities for malignant transformation to occur which can lead to the
development of multiple myeloma.1,2

Multiple myeloma develops from unique multi-step precursor stages where
aberrant plasma cells become increasingly malignant. The first stage,
monoclonal gammopathy of undetermined significance (MGUS) is asymptomatic
and characterized by the presence of serum M-protein, less than 10% clonal
plasma cells residing in the bone marrow and absence of end organ damage that
is characterized by serum calcium, renal insufficiency, anemia, lytic bone lesionsCRAB criteria.3 While not all cases of MGUS progress to multiple myeloma
(approximately 1% increase per year), it can be appreciated that multiple
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myeloma is frequently preceded by MGUS.4,5 Smoldering multiple myeloma
(SMM) is characterized by more than 10% of clonal plasma cells residing in the
bone marrow with absence of CRAB freatures.3 The disease progresses to
multiple myeloma when CRAB features are manifested. Occasionally, multiple
myeloma can progress to plasma cell leukemia, the most malignant form of the
disease. Plasma cell leukemia exists when malignant plasma cells become
independent of survival signals from the bone marrow microenvironment and are
able to invade the peripheral blood and other organs.1 The stepwise process
evolution from MGUS to SMM to multiple myeloma is orchestrated through
multiple mechanisms involving DNA damaging events, reorganization of the bone
marrow (BM) microenvironment, and escaping immune surveillance. This
multifocal etiology of multiple myeloma is complex. While this project focuses on
the interaction between the immune system and multiple myeloma, the
underlying genetic events are important for understanding the origin of this
disease.

Oncogenic transformation
The transformation of normal plasma cells into multiple myeloma involves
the acquisition of several different genetic abnormalities. Genetic drivers of
multiple myeloma are often classified into primary and secondary events. Primary
events involve large-scale genetic changes that include immunoglobulin heavy
chain (IgH) translocations, hyperdiploidy, and cyclin D overexpression.1,3
Secondary events involve mutations in common oncogenes such as NRAS,
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KRA, BRAF, NF-κB pathway, p53, PTEN, and RB inactivation.3 While the genetic
abnormalities that occur in multiple myeloma patients are heterogeneous, the
initiating events follow a common theme involving gains of chromosomes (such
as 5, 9, 15, 19) or IgH translocation events that result in oncogene expression
being driven by a strong enhancer region of the immunoglobulin (Ig) genes.1 The
overexpression of the initial oncogenes can promote the accumulation of
subsequent mutations leading to the development of multiple myeloma.

Bone marrow microenvironment reorganization
Genetic sequencing studies have revealed little differences between
MGUS and multiple myeloma patients, highlighting the importance of the BM
microenvironment in the progression of multiple myeloma.6,7 The BM
microenvironment is composed of an intricate network of cells (BM stromal cells,
osteoblasts, osteoclasts, endothelial cells, lymphocytes, myeloid cells) which play
integral roles in hematopoiesis. As mirrored in many other solid tumor types, the
BM microenvironment becomes dysregulated and customized to promote
myelomagenesis. The bone marrow reorganization is largely due to the effects of
a master regulator cytokine, Interleukin-6 (IL-6).

Interactions between myeloma cells and BM stromal cells can lead to the
secretion of IL-6 via the NF-κB pathway. IL-6 also influences multiple signaling
axes (PI3K/Akt, JAK/Stat, NF-κB, Wnt), all of which become dysregulated to
support the growth, survival and drug resistance of multiple myeloma.8,9 One of
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the hallmark features of the BM microenvironment transformation mediated by
multiple myeloma is the imbalance between osteoclasts and osteoblasts.
Osteoclast activation leads to osteolysis and reduced osteoblast-mediated bone
formation.9,10

Solo, IL-6 also functions as a potent growth, survival and drug resistance
factor and adversely affects the immune cells of the BM microenvironment
leading to an immunosuppressive milieu.8 The potency of IL-6 in
myelomagenesis is highlighted by the observations that when inhibited (via antiIL-6 antibodies) multiple myeloma cell proliferation decreased and cells were resensitized to anti-myeloma drugs, dexamethasone and bortezomib.11 However,
promising patient outcomes have yet to be observed in clinical trials targeting IL6, suggesting targeting IL-6 alone is not sufficient for the treatment of multiple
myeloma.12

Immune escape
Transformation of the immune microenvironment is critical to myeloma
pathogenesis. Key components of the immune microenvironment consist of
dendritic cells (DC), T cells, and myeloid derived suppressor cells (MDSC).
Changes are found in each cell type, which contributes to the establishment of an
immunosuppressive environment for multiple myeloma survival.
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DCs have defective antigen presentation abilities in the context of multiple
myeloma. This critical process is integral to the stimulation of cytotoxic T cell
lymphocytes (CTL). There is a paucity of DCs observed in myeloma patients and
furthermore, mature DCs in myeloma patients show reduced expression of costimulatory molecules (CD40 and CD80) and lower expression of HLA-DR.13

Due to the plasticity of CD4 T cell development, a process heavily
influenced by cytokines, the balance of T cell subsets in multiple myeloma is
perturbed. The abundance of IL-4 and IL-10 in the BM microenvironment skews
T cell development towards a Th2 phenotype rather than a Th1 phenotype,
therefore favoring immune suppression.14 The role of T-regulatory cells (T-reg) is
less understood in the context of myeloma due to the compartment they are
analyzed from (peripheral blood vs. bone marrow) and the methods used for
analysis (phenotypic vs functional). Some groups have demonstrated an
abundance of T-regs while others have shown low T-reg percentages in the
myeloma BM.13,14 However, it is well appreciated that the myeloma-derived Tregs are dysfunctional and have profound differences compared to their health
counterparts. Due to the effects of IL-6, the balance between Th1, Th17 and Treg cells heavily favors the Th17 phenotype. Th17 cells in turn produce IL-17,
which has been shown to promote multiple myeloma cell growth, suppress T cell
anti-tumor activities, and contribute to osteolytic bone disease.13,14
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Additionally, MDSCs contribute to defective T cell mediated immunity.
Studies have shown MDSC populations to be elevated in multiple myeloma
patients compared to healthy controls.13,15 Additionally, these cells produce
arginase-1 which directly promotes myeloma tumor growth as well as depletes
the extracellular matrix of arginine, an important amino acid for T cell activity.13,14
MDSC also aid in myelomagenesis by assisting in the promotion of osteolytic
bone disease as these cells can function as osteoclast progenitors.14 Key studies
have also shown that myeloma cells can induce the development of MDSCs from
monocytes, establishing a feedback loop that promotes multiple myeloma
progression.15

The network between multiple myeloma and the BM microenvironment is
critical when considering new treatment strategies of multiple myeloma. This
project aims to highlight an important interaction between multiple myeloma and
myeloid cells that can be harnessed for new immunotherapy opportunities.

1.2 Immunotherapy for the treatment of multiple myeloma
The immune system is heavily implicated in the pathogenesis of multiple
myeloma, suggesting many opportunities for therapeutic intervention. This has
led to the recently increased interest in applying immunotherapy for the treatment
of multiple myeloma.

6

Proteasome inhibitors and Immune modulatory drugs
The introduction of proteasome inhibitors (PI) and immune modulatory
drugs (IMIDs) has changed the landscape of myeloma therapy, improving patient
survival and outcomes.16,17 Proteasome inhibitors (bortezomib, carfilzomib) target
the proteasome and inhibit intracellular protein degradation, causing cell cycle
arrest through the endoplasmic reticulum (ER) stress response and apoptosis
through the activation the unfolded protein response and activation of caspse-8
and 9.18,19 Bortezomib is a boronate PI that inhibits the β5 subunit of the
proteasome and was the first PI to see clinical success for the treatment of
myeloma. Now, next generation PIs, carfilzomib and ixazomib, are currently
being investigated in clinical trials and show promise as more potent options to
bortezomib.20 Since bortezomib affects the proteasome, a key component in
antigen presentation, we further investigated how bortezomib affects the ability of
multiple myeloma to cross-present antigens.

IMiDs (thalidomide, lenalidomide, pomalidomide) have multiple
mechanisms of action that include both augmenting the immune system and
direct anti-myeloma activity. These mechanisms involve promoting the
production of IL-2, interferon (INF) γ and other pro-inflammatory cytokines that
activate T cells and natural killer (NK) cells.21 Lenalidomide has also been
demonstrated to induce the expression of DC maturation markers to promote
antigen presentation to T cells.22 Currently, lenalidomide, in combination with
other myeloma therapies is one of the standard of care treatments for newly
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diagnosed patients.23 In this present work, we sought to determine how
lenalidomide could modulate cross-presentation by multiple myeloma.

Allogeneic stem cell transplant
While multiple myeloma remains incurable with standard therapies, which
include autologous stem cell transplant (auto-SCT), allogeneic stem cell
transplant (allo-SCT) has remained the only curative option for patients. This
treatment strategy relies on a potent conditioning chemotherapy regimen that
ablates the patient's bone marrow, followed by the infusion of stem cells (and
other cellular components) from an HLA-matched-healthy donor to achieve a
graft vs. myeloma (GvM) effect. The difficulty and limitation of this therapy comes
from its highly toxic side effects such as graft vs. host disease (GvHD), where
donor-derived T cells mount an immune response that targets host normal
tissues. Oftentimes, the benefits of GvM are outweighed by the toxicity of alloSCT, which includes the side effects of the conditioning regimen as well as
GvHD. Additionally, multiple myeloma is more often diagnosed in elderly patients
who are more susceptible to the side effects of the myeloablative conditioning
regimens, limiting this therapy to younger and healthier patients.24,25 Therefore,
there is an interest in identifying new immunotherapies, that offer a more targeted
approach and less side effects, that can be more widely used to treat multiple
myeloma patients.
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Targeting multiple myeloma antigens with immunotherapies
Currently the most promising immunotherapies used to treat multiple
myeloma target myeloma-associated antigens. There are only a handful of
myeloma-specific antigens, most commonly cancer testis antigens (MAGE-A3
and NY-ESO-1). These targets are under current investigation in ongoing clinical
trials.26 Most of the current immunotherapies target myeloma-associated
antigens, proteins and antigens that are enriched on the surface of myeloma and
plasma cells. The immunotherapy modalities currently under investigation are
similar to the immunotherapies being used in other tumor settings such as
monoclonal antibodies, chimeric antigen receptor T cells (CAR-T), bispecific T
cell engagers (BiTE), and immune checkpoint inhibition.

To date, two monoclonal antibodies are clinically FDA approved for the
treatment of multiple myeloma: daratumumab (targets CD38) and elotuzumab
(targets SLAMF7). CD38 is highly expressed on plasma cells, NK cells, and
myeloid cells. Daratumumab has multiple methods of activity including
complement-dependent cytotoxicity (CDC), antibody-dependent cytotoxicity
(ADCC) as well as Treg and MDSC-inhibition.27,28 Similarly elotuzumab also has
ADCC activity and can activate NK cells as SLAMF7 is highly expressed on both
plasma cells and NK cells.29 CAR-T cells are genetically engineered T cells that
have the antigen recognition regions of a monoclonal antibody linked to the TCR
domains and co-stimulatory domains, resulting in a T cell that can directly
recognize an antigen of choice. CAR-T cells have been used in the setting of
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multiple myeloma, targeting CD19 and B cell maturation antigen (BCMA).
Additionally, CD19 has been targeted using BiTE and preclinical studies have
investigated targeting CD38 and CD138.30 Immune checkpoint inhibition through
the use of blocking antibodies is also under investigation in multiple myeloma.
Program death-ligand 1 (PD-L1) expression is upregulated on myeloma cells in
patients and its receptor, programmed cell death protein-1 (PD-1) expression is
elevated on the T cells and NK cells.31

While there are a number of multiple myeloma targets and different
immunotherapeutic strategies under investigation, many of these aforementioned
treatments have yielded promising but limited clinical results, mainly as they fail
to fully eradicate the underling multiple myeloma. Thus, there is a continued need
for further investigation into improving the current modalities and searching for
novel immunotherapies.

1.3 Antigen presentation and cross-presentation
While the exact mechanisms of how multiple myeloma avoids immune
destruction remain unclear, it is clear that CD8+ T cells fail to manage the
outgrowth and expansion of multiple myeloma cells. A critical step in T cell
activation occurs through the ability of both dendritic cells and tumor cells to
present antigen. Moreover, downregulation of antigen presentation is a common
strategy employed by tumor cells to avoid immune detection.32 Therefore, in this
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present work we focused on investigating the biology of antigen presentation in
multiple myeloma.

Human leukocyte antigen system
Antigen presentation is the process by which antigens, usually proteins,
are degraded intracellularly into small peptide fragments that are displayed on
the cell surface in the context of human leukocyte antigen (HLA) class I and class
II molecules for recognition by T cells. HLA class I is a heterodimer cell surface
molecule that consists of a α-heavy chain which is encoded by the highly
polymorphic HLA gene (HLA-A, -B, and -C) and β2-microglobulin, and presents
antigens recognized by CD8+ T cells. HLA class II molecules (HLA-DM, -DP, DO, -DQ, -DR) are also heterodimers, but consist of a α-chain and β-chain-both
of which are encoded by HLA genes and presents antigens to CD4+ T cells. The
polymorphisms of the HLA genes allows for fine-tuning of the adaptive immune
responses and plays a major role in hematopoietic and solid organ
transplantation. The HLA-A2 haplotype has garnered interest due to having the
highest frequency among the Caucasian population. Importantly, HLA class I
downregulation does not appear to be a common immune escape mechanism in
multiple myeloma, as it can be for other tumor types. However, Racanelli and
colleagues have demonstrated that while antigen presentation in multiple
myeloma cells is altered, many of the components of the antigen presentation
machinery (APM) were upregulated in multiple myeloma patients.33 Additionally,
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work from our group has suggested that HLA class I is abundantly expressed on
the cell surface of multiple myeloma.33,34

Antigen presentation pathway
The mechanism by which HLA molecules present antigens to the immune
system is accomplished through an organized, step-wise process known as the
antigen presentation pathway (Figure 1). Classically, HLA class I molecules
display antigens that are expressed endogenously in the cytosol. Intracellular
proteins are first targeted for degradation by the proteasome, which facilitates the
generation of small, 8-10 amino acid peptides that are favored for HLA class I
binding. Unfolded, immature HLA class I heavy chain molecules reside in the ER
and are stabilized by the chaperon protein-calnexin (CNX) before binding to β2microglobulin (β2M). Upon β2M binding, HLA molecules are stabilized and
subsequently released from CNX. Next, HLA binds to the peptide-loading
complex (PLC) consisting of calreticulin, tapasin and transporter associated with
antigen processing protein 1 and 2 (TAP1/2).

The peptides are transported from the cytosol into the ER via the TAP1/2
protein where they interact with the PLC and HLA. The PLC orchestrates both
peptide editing and binding to HLA to allow for proper binding to HLA. Once a
high affinity peptide binds to the peptide groove of HLA, the HLA molecule is
released from the PLC and shuttled through the ER to Golgi transport and
displayed on the cell surface to interact with CD8+ T cells. While this pathway

12

facilitates endogenous peptide recognition, exogenous peptides can also be
displayed to cytotoxic T cells via the cross-presentation pathway.
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Figure 1: Overview of the antigen presentation pathway.

Figure 1: Overview of the antigen presentation pathway. Unfolded HLA class
I molecules reside in the ER, stabilized by calnexin. Upon β2M binding, HLA
class I molecules bind to the peptide-loading complex composed of calreticulin,
TAP1/2, and tapasin. Endogenous antigens are loaded onto HLA class I
molecules after being processed by the proteasome in the cytoplasm. Antigens
are then transported into the ER lumen via TAP1/2 where they bind to HLA class
I. Upon binding a high affinity peptide, HLA class I molecules are then shuttled to
the cell surface through the endocytic pathway.
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Cross-presentation
Cross-presentation is integral to the anti-tumor immune response as it
allows DC priming of naïve CD8+ T cells against exogenous antigens. Much of
how exogenous antigens are processed and cross-presented mirrors the
pathway of how endogenous antigens are presented with a few notable unique
characteristics.35

The defined means by which peptides are initially transported from the
microenvironment into the cytosol remains an area of active research. There are
three popular models that describe cross-presentation. The first model is the
cytosolic pathway model. In this model, the antigen is internalized in a
phagosome through phagocytosis. In the phagosome, the antigen can be
exported to the cytosol for proteasomal degradation. The processed antigen can
then either be loaded onto HLA class I molecules in the ER (similar to classical
antigen presentation) or re-imported into the phagosome which can contain its
own PLC and HLA class I molecules.36-38 Alternatively, in the vacuolar model,
internalized antigens are processed by phagosomal degradation and loaded onto
HLA class I molecules in the phagosome.36 The peptide exchange model
describes another possible mechanism of how exogenous peptides are imported
into the cell. In this model, surface HLA class I molecules that have already
bound peptide are recycled back into the phagosome where old peptides can
exchange for newly generated exogenous peptides.37,38 HLA class I reinternalization is facilitated through monoubiquitination of a conserved lysine
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residue (tyrosine in mouse) in the cytosolic tail of the HLA class I molecule.37,39
Importantly, the peptide exchange model offers a TAP-independent mechanism
for exogenous peptide loading.

Cross-presentation has previously been limited to hematopoietic cells,
specifically professional antigen presenting cells (APC; notably DC,
macrophages, and B cells). However, recent work from our group has
demonstrated that solid tumor cells (breast cancer, melanoma, lung cancer) are
capable of cross-presentation.40-44 In the case of multiple myeloma, we
hypothesized multiple myeloma can cross-present antigen, due to their
hematopoietic lineage.

1.4 PR1 as an immunotherapeutic target
Neutrophil elastase, proteinase 3, and PR1
Neutrophil elastase (NE) and proteinase 3 (P3) are two myeloid azurophil
granule specific serine proteases expressed by myeloid progenitor cells,
polymorphonuclear leukocytes (PMNs) and monocytes. NE and P3 possess
normal antimicrobial effects in the context of inflammation. These serine
proteases reside in the azurophil granules; specialized lysosomes within the
neutrophil, where pathogenic proteins are hydrolyzed. Additionally, NE can be
secreted from the neutrophil into the extracellular matrix during inflammatory
conditions.45
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PR1 (sequence: VLQELNVTV) is a nonameric HLA-A*0201 (HLA-A2)
restricted peptide derived from NE (amino acids 168-176) and P3 (amino acids
128-136).46 PR1 was originally discovered and characterized from acute myeloid
leukemia (AML) and chronic myelogenous leukemia (CML). In these tumor
settings, NE and P3 are aberrantly expressed, making PR1 an attractive tumor
antigen for immunotherapy.41,46-48 While this would appear to limit PR1 as a
therapeutic target to only hematologic malignancies that aberrantly express NE
and P3, there is a preponderance of work from our group that suggests PR1 can
be targeted in other tumor types via cross-presentation of NE and P3. Prior to
this current work, our group has demonstrated that non-myeloid tumor types
(breast cancer, melanoma, lung cancer) can take up and internalize NE/P3 from
neutrophils and cross-present PR1 in the context of HLA-A2.40-44

PR1-targeting immunotherapies
We first demonstrated the feasibility of targeting PR1 with immunotherapy in
patients with relapsed/refractory AML, CML, and myelodysplastic syndrome
using a PR1-peptide vaccine and demonstrated that vaccination can achieve
objective clinical responses.49 We further developed a T-cell receptor (TCR)-like
monoclonal antibody that recognizes the PR1/HLA-A2 complex (8F4 antibody).
The 8F4 antibody is unique in that it recognizes the combined epitope of the
PR1/HLA-A2 complex, mimicking the manner by which TCRs recognize
peptide:HLA complexes. However, 8F4 retains the high binding affinity of an
antibody (dissociation constant [KD] = 9.9nM).50,51
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8F4 has shown broad anti-leukemia activity against AML cell lines, primary
AML patient samples, and patient derived xenograft models. Specifically, our
group has illustrated that 8F4 antibody can induce complement-dependent
cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) against
AML in vitro and specifically inhibits growth of AML progenitor cells.50
Furthermore, we have also shown that 8F4 has anti-leukemia functionality
against primary human AML cells in vivo by reducing the leukemia burden,
extending survival, and inhibiting AML engraftment in human xenograft mouse
models.52 Based on the success of this work 8F4 is currently being tested in an
ongoing Phase I/II clinical trial.

Based on the unique characteristics of multiple myeloma and its
microenvironment, we hypothesize that multiple myeloma can take up NE and P3
and subsequently cross-present the PR1 peptide on the cell surface, rendering
multiple myeloma susceptible to PR1-targeting immunotherapies. This
hypothesis is based on the observation that multiple myeloma is a malignant
plasma cell, which originates from the B cell lineage (a known APC), suggesting
these cells will be capable of cross-presentation. Additionally, the bone marrow
microenvironment, where multiple myeloma homes to, is rich in myeloid
progenitor cells and PMNs, providing an abundant source of NE and P3 for PR1
cross-presentation.
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Chapter 2: Materials and Methods
The following chapter is based on my publication, used with permission granted
by AACR Journals.
Alatrash, G.1, Perakis, A.A.1, Kerros, C., Peters, H.L., Sukhumalchandra, P.,
Zhang, M., Jakher, H., Zope, M., Patenia, R., Sergeeva, A., Yi, S., Young, K.H.,
Philips, A.V., Cernosek, A.M., Garber, H.R., Qiao, N., Weng, J., St John, L.S.,
Lu, S., Clise-Dwyer, K., Mittendorf, E.A., Ma, Q. & Molldrem, J.J. Targeting the
Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple
Myeloma. Clin Cancer Res 24, 3386-3396 (2018).
2.1 Cells and cell culture
Arkansas (ARK), LP-1, ARP-1, IM-9, OPM-2, RPMI 8226 and U266
multiple myeloma cell lines, U937 histiocytic leukemia cell line, T2 T/B cell
hybridoma cell line, H2023 lung cancer cell line, and T-47D and MDA-MB-453
breast cancer cell lines were all acquired from ATCC. All cell lines were cultured
in RPMI 1640 media with 25 mmol/L HEPES + l-glutamine (Hyclone) and
supplemented with 10% fetal bovine serum (Gemini Bio-Products), 100 U/mL
penicillin, and 100 μg/mL streptomycin (Cellgro). All cell lines were cultured in 5%
CO2 incubator at 37°C. All cell lines were thoroughly verified using short tandem
repeat DNA fingerprinting performed at the MD Anderson Sequencing and
Microarray Facility.

2.2 RT-PCR
Cell mRNA was purified from cell lines using RNA Stat 60 kit (TelTest) and
cDNA was synthesized using Gene AMP RNA kit (Perkin Elmer). Amplification of
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cDNA was performed using iCycler (Bio-Rad) using the following primer sets: NE
forward primer 5′-CACGGAGGGGCAGAGACC-3′ and NE reverse primer 5′TATTGTGCCAGATGCTGGAG-3′; P3 forward primer 5’GACCCCACCATGGCTCAC-3’ and P3 reverse primer 5’ATGGGAAGGACAGACAGGAG-3’; actin forward primer 5’CCAGAGCAAGAGAGCTATCC-3’ and actin reverse primer 5’CTGTGGTGGTGAAGCTGTAG-3’.40,53 DNA was separated on 1.5% agarose gel
and detected using GelDoc2000 (Bio-Rad).

2.3 Western blotting
Cell lysates were prepared for western blotting by resuspending cell
pellets in lysis buffer (10 mM/L HEPES [pH 7.9], 10mM/L KCl, 0.1mM/L EGTA
0.1mM/L EDTA, 1 mM/LDTT) containing proteases inhibitors (Thermo Fisher
Scientific). Lysis reaction was performed for 30 minutes at 4°C. Protein
concentrations were calculated using standard Bradford assay (Bio-Rad).
Protein separated on 10% SDS gels (Bio-Rad) using electrophoresis under
reducing conditions and transferred onto polyvinylidene fluoride membranes.
Prior to immunoblotting, membranes were blocked with 5% milk solutions in
0.05% TBS-Tween. Membranes were probed using antibodies against NE (Santa
Cruz Biotechnology), P3 (NeoMarkers), actin (Millipore), GAPDH (Millipore),
Calnexin, LMP2, LMP7, Tapasin (all Cell Signaling), TAP1 (Enzo Life Sciences),
Pan-HLA (HC-10 hybridoma) and peroxidase-conjugated secondary antibodies
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(Jackson ImmunoResearch). Chemiluminescence signal was measured on film
(Kodak) and digitally using ChemiDoc Touch Imaging System (Bio-Rad).

2.4 Antigen cross-presentation assay
Cells were cultured with 10μg NE, P3 (Athens Research & Technology),
EndoGrade ovalbumin (Ova; Hyglos) or irradiated PMNs or peripheral blood
mononuclear cells (PBMCs; 1:1 ratio) at varying durations. Cells were
permeabilized by washing in Perm/Wash buffer (BD Biosciences) and stained
with fluorochrome-conjugated antibodies (Invitrogen) against P3 (Thermo
Scientific) or NE (Santa Cruz Biotechnology). Cross-presentation of peptides was
measured by staining with fluorescently conjugated anti-PR1/HLA-A2 antibody
(8F4). Inhibition of cross-presentation was accomplished by treating cell cultures
with the endoplasmic reticulum (ER) to Golgi anterograde inhibitor, brefeldin A
(Sigma-Aldrich), or proteasome inhibitors, lactacystin (Sigma-Aldrich) or
bortezomib (Millennium Pharmaceuticals). To determine the effect of IMiDs on
cross-presentation, cell cultures were treated with lenalidomide (Celgene).

2.5 Peptide-specific CTL generation
PR1-specific CTL were generated from HLA-A2 healthy donor PBMC by
stimulating with PR1 peptide (Bio-synthesis Inc.) in vitro. PBMC from healthy
donor leukapheresis were isolated using Histopaque 1077 gradient centrifugation
(Sigma-Aldrich) and were co-cultured with PR1 (20 μg/mL)-pulsed T2 cells at 1:1
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ratio in RPMI 1640 media supplemented with 10% human AB serum (Gemini
Bio-Products). Cell cultures were restimulated with PR1-pulsed T2 cells and 20
IU/mL of recombinant human IL-2 (Biosource International) on days 7, 14, and
21.
2.6 Cell-mediated cytotoxicity assay
Target cells (1x 103 cells/mL) were fluorescently labeled with calcein-AM
(Invitrogen) for 15 minutes at 37°C and then thoroughly washed with RPMI 1640
to remove free calcein-AM. Target cells were co-cultured with peptide specific
CTL at indicated effector-to-target (E:T) ratios for 4 hours at 37°C in 60 well
Terasaki plates. Trypan blue was added to each well to stop the reaction. The
fluorescence was measured on a CytoFluor II plate reader (Applied Biosystems).
The percent cytotoxicity was calculated as follows:
((1 − 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑒𝑛𝑐𝑒-./01-213314-5/ – 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑒𝑛𝑐𝑒819:. )/𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑒𝑛𝑐𝑒-./01- .=5>1 −
𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑒𝑛𝑐𝑒819:. )) × 100

2.7 Complement-mediated cytotoxicity assay
U266 cells (1x 106 cells) were cultured with soluble NE or P3 for 24 hours
and then labeled with calcein AM. U266 cells were resuspended in serum-free
RPMI 1640 media and treated with anti-PR1/HLA-A2 antibody (8F4) or isotype
control antibody for 10 minutes at 37°C. Standard rabbit complement (C’)
(Cedarlane Labs) was added and cells were incubated for 60 minutes at 37°C.
Fluorescence was measured and cytotoxicity was measured as described in
section 2.6.
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2.8 Staining for PR1-CTL in multiple myeloma patient samples
Patient and HD peripheral blood (PB) samples and BM aspirates were
collected after informed consent to participate in an MD Anderson Cancer Center
institutional review board-approved study. PBMC were isolated using Histopaque
1077 gradient centrifugation (Sigma-Aldrich). PBMC were stained using the
following fluorescent antibodies: CD8 APC-H7 (BD), CD3 FITC (BD), PEconjugated PR1/HLA-A2-dextramer (Immudex) or tetramer (Baylor College of
Medicine MHC Tetramer Core (Houston, TX) and the following pacific blue
conjugated lineage antibodies: CD4 (BD), CD14 (BD), CD16 (BD) and CD19
(Biolegend). Samples were fixed with 4% paraformaldehyde. Data were acquired
on a Canto flow cytometer (BD Biosciences) and analyzed using FlowJo software
(Tree Star). The frequency of PR1-CTL was determined as the percentage of live
cells that were lineage-, CD3+, CD8+ and PR1-dextramer+ or tetramer+.
Phenotype of PR1-CTL (PR1/HLA-A2-dextramer+) was investigated using CCR7
PE-Cy7 (Biolegend) and CD45RA PerCP-Cy5.5 (Biolegend) staining, and was
classified as central memory (CCR7+/CD45RA-), effector memory (CCR7/CD45RA-), naïve (CCR7+/CD45RA+) or terminally differentiated (CCR7/CD45RA+).

2.9 Confocal staining and imaging
Bone marrow smears and U266 cells were fixed with cold acetone and
blocked with 5% normal mouse serum (Jackson ImmunoResearch). Fixed slides
were washed with PBS and then double stained with Alexa-647 conjugated 8F4
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antibody and Alexa-488 conjugated mouse anti-human HLA-A2 antibody
(Serotec) or Alexa-488 conjugated rabbit anti-CD138 antibody (Bioss). Slides
were stained with antibodies for 90 minutes at room temperature. After washing,
ProLong Gold antifade reagent with DAPI (Invitrogen) was added. Confocal
imaging was performed using Leica Microsystems SP2 SE confocal microscope
with 10x/25 air, 63x/1.4 oil objectives. Leica LCS software (version 2.61) was
used for image analysis.

2.10 U266 myeloma xenograft animal model
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) female mice were purchased from
Jackson Laboratory and housed at MDACC following International Animal Care
and Use Committee-approved protocol. Mice received sublethal irradiation 24
hours prior to intravenous injection with 2x106 U266 cells 54. U266 engraftment
and disease burden was measured by quantifying blood human IgE level by
ELISA (Bethyl Laboratories). Mice were treated intravenously with 0.5 x 106 PR1CTL, irrelevant peptide (CG1, E75)-CTL or left untreated (PBS-treated) 14 days
after U266 engraftment. Mice were treated intravenously with 8F4 antibody
(10mg/kg) or IgG1 isotype control (Herceptin, 10mg/kg) three-times per week
beginning on day 28 for a total of 10 injections.52 Mice that received bortezomib
(Millennium Pharmaceuticals) or carfilzomib (Sellek Chemicals) received four
weekly intravenous injections of the respective proteasome inhibitor (0.025
mg/kg). Mice were sacrificed 35 days after CTL infusion or 3-4 days after last
antibody treatment, and bone marrow was harvested, stained with mouse CD45,
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human (h) CD45, hCD138, and HLA-A2 fluorescently conjugated antibodies and
then analyzed by flow cytometry.

2.11 Annexin V apoptosis assay
U266 cells were co-cultured with irradiated PMN (1:3 ratio) for 24 hours
prior to experimentation. The next day, U266 (2x105 per well) were seeded into a
96-well plate and resuspended in fresh medium. U937-WT (U937-wild type) and
U937-A2 (U937-HLA-A2 transduced) cells were used as negative and positive
controls respectively. Cells were treated with either 8F4 alone (2 mg/mL),
bortezomib alone (2.5 nM, Millennium Pharmaceuticals) or in combination
overnight at 37°C. Cross-linking antibody Fab fragments were added to cells
(Jackson ImmunoResearch) to facilitate 8F4 mediated apoptosis. Cells were then
washed in PBS and intracellularly stained for Annexin V (BD Biosciences),
propidium iodide (BD Biosciences), and anti-CD138 (Biolegend) to identify U266
cells in a 96 well plate. Cells were analyzed on a LSR Fortessa (BD Biosciences)
and FlowJo software (Tree Star). Apoptosis percentages were calculated by
adding the Annexin V+ and Annexin V+PI+ gates.

2.12 Statistical analysis
All statistical analyses were calculated using GraphPad Prism 6.0 and 7.0
software. Significance was determined for p values less than 0.05.
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Chapter 3: Specific Aims
Aim 1: Determine the extent of NE and P3 uptake and PR1 crosspresentation by multiple myeloma

Cross-presentation of extracellular proteins has been demonstrated in
several other tumor types (breast cancer, melanoma, lung cancer).40-44 Since
multiple myeloma differentiates from the B cell, a known APC, we hypothesize
that multiple myeloma has the capability to take up NE and P3 and subsequently
cross-present the PR1 peptide on the cell surface. Lack of endogenous transcript
and protein expression of NE and P3 will be determined in multiple myeloma cell
lines by RT-PCR and western blot analysis respectively. The ability of multiple
myeloma cell lines to take up NE and P3 from soluble and cellular sources will be
determined using flow-based assays by staining for internalized NE and P3
protein. Cross-presentation of PR1 by multiple myeloma will be measured by
staining for PR1/HLA-A2 surface expression using the 8F4 antibody.

Aim 2: Evaluate the susceptibility of multiple myeloma to PR1-targeting
immunotherapies

PR1-targeting immunotherapies have been utilized with great success for
the treatment of myeloid malignancies.40,49,50,52,55-58 We hypothesize that crosspresentation of PR1 will render multiple myeloma susceptible to
immunotherapies targeting PR1. Susceptibility to PR1-targeting immunotherapies
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will be investigated using PR1-specific CTL and 8F4 antibody. The HLA-A2+
U266 multiple myeloma cell line will be co-cultured with NE and P3 to facilitate
cross-presentation of PR1 and will be co-cultured with PR1-CTL or 8F4 antibody.
Cytotoxicity to PR1-targeting immunotherapies will be measured in vitro using
calcein-AM cytotoxicity assays. The therapeutic ability of 8F4 antibody to
eliminate human multiple myeloma in vivo will be investigated using a human
multiple myeloma xenograft mouse model. Human U266 multiple myeloma cells
will be transplanted into NSG mice. Mice will be treated with PR1-CTL or 8F4
antibody. Bioluminescent imaging and ELISA will be used to measure disease
progression and assess the therapeutic potential of 8F4 in multiple myeloma.
Additionally, we will investigate how 8F4 can be integrated into standard of care
therapies for multiple myeloma. Xenograft mice will be treated with 8F4 in
combination with bortezomib, a standard of care multiple myeloma
chemotherapy, to determine whether efficacy can be further increased with a
combinatorial therapy approach.
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Chapter 4: Determine the extent of NE and P3 uptake and
PR1 cross-presentation by multiple myeloma
The following chapter is based on my publication, used with permission granted
by AACR Journals.
Alatrash, G.1, Perakis, A.A.1, Kerros, C., Peters, H.L., Sukhumalchandra, P.,
Zhang, M., Jakher, H., Zope, M., Patenia, R., Sergeeva, A., Yi, S., Young, K.H.,
Philips, A.V., Cernosek, A.M., Garber, H.R., Qiao, N., Weng, J., St John, L.S.,
Lu, S., Clise-Dwyer, K., Mittendorf, E.A., Ma, Q. & Molldrem, J.J. Targeting the
Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple
Myeloma. Clin Cancer Res 24, 3386-3396 (2018).

4.1 Multiple myeloma cells lacking endogenous NE and P3 internalize
exogenous proteins
To determine if multiple myeloma cells express NE and P3, a panel of
multiple myeloma cell lines was analyzed for endogenous expression of these
PGP. Our data indicate that NE and P3 are absent in multiple myeloma cells at
the transcript and protein levels (Figure 2A and B). These findings are in
agreement with reports from the Cancer Cell Line Encyclopedia,59 which confirm
the lack of NE and P3 in multiple myeloma (Figure 3A and B). The absence of
NE and P3 in multiple myeloma is expected since multiple myeloma is of
lymphoid origin, which is known to be deficient in myeloid primary granule
proteins.60 The myelomonocytic U937 leukemia cell line that endogenously
expresses NE and P3 was used as a positive control in these experiments.
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Figure 2. Multiple myeloma cells lack endogenous NE and P3.
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Figure 2. Multiple myeloma cells lack endogenous NE and P3. Protein (A)
and mRNA (B) was extracted from multiple myeloma cell lines. (A) Immunoblots
demonstrate lack of NE and P3 proteins in whole cell lysates from seven different
multiple myeloma cell lines. Gels were loaded with 20 μg of protein. (B) RT-PCR
was performed using NE and P3 primers, which shows lack of NE and P3 mRNA
expression in multiple myeloma cell lines. U937 myelomonocytic AML cell line
was used as a positive control. β-actin was used as a loading control. The first
lane in each figure represents the molecular weight (MW) marker.
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Figure 3. Transcript expression of NE and P3 genes in Cancer Cell Line
Encyclopedia (CCLE).
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Figure 3. Transcript expression of NE and P3 genes in Cancer Cell Line
Encyclopedia (CCLE). Transcript expression of ELANE (A) and PRNT3 (B)
from cell lines was accessed from the CCLE for the following hematological
malignancies: multiple myeloma, (MM, 25), acute myeloid leukemia (AML, 36),
acute lymphoblastic leukemia (ALL, 16), Burkett’s lymphoma (11), chronic
myelogenous leukemia (CML, 14), B cell lymphoma (42), T cell lymphoma (5), T
cell leukemia (16), chronic lymphocytic leukemia (CLL, 3). Parentheses indicate
the number of cell lines.
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4.2 HLA-A2+ multiple myeloma cells take up and cross-present NE and P3
from soluble and cell-associated sources
Since we previously showed that solid tumors and B cells take up NE and
P3,40,41,43,53,61,62 we next tested whether multiple myeloma cells take up NE and
P3, the first step in antigen cross-presentation. We co-cultured a number of
multiple myeloma cell lines with soluble NE or P3 over increasing durations. Flow
cytometry analysis of intracellular NE and P3 staining demonstrates that NE and
P3 are taken up by multiple myeloma (Figure 4A and B). Time-dependent
internalization of NE and P3 is observed, with a marked difference in the
magnitude of uptake between NE and P3. Our data indicates that soluble P3 is
more efficiently internalized compared to NE by multiple myeloma cell lines. The
uptake of both proteins is sustained throughout the duration of the cultures. The
kinetics and degree of NE and P3 uptake by the multiple myeloma cell lines
closely resembles the pattern of NE and P3 uptake observed in breast cancer
and melanoma.
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Figure 4. Multiple myeloma cells internalize exogenous NE and P3.
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Figure 4. Multiple myeloma cells internalize exogenous NE and P3.
Flow cytometry detected intracellular NE and P3 in multiple myeloma cell lines
following culture with NE (10 μg/mL) (A) or P3 (10 μg/mL) (B). After incubation,
cells were permeabilized and stained with either anti-NE or anti-P3 antibodies.
Graphs display the mean ± SEM fold increase in median fluorescence intensity
(MFI) over untreated cells from triplicate wells from six independent experiments.
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Since PR1 is an HLA-A2-restricted epitope, we focused our crosspresentation studies on the HLA-A2+ (i.e., HLA-A*0201) U266 multiple myeloma
cell line. In agreement with the panel of multiple myeloma cell lines we examined
(Figure 4A and B) we confirmed the internalization of soluble and PMNassociated NE and P3 by U266 cells (Figure 5A and B; Figure 6A and B).
Previously, we demonstrated that solid tumor cells can cross-present PR1 from
both soluble and cell-associated sources of NE and P3.40,43 These findings were
recapitulated in the U266 multiple myeloma cells that were co-cultured with
soluble NE, P3 or irradiated HLA-A2- PMN, the latter serving as the cellular
source of NE and P3 that lack endogenous PR1 (Figure 7A and B).

As shown previously, cross-presentation was demonstrated by staining
cells with anti-PR1/HLA-A2 Alexa-647-conjugated antibody.40 Due to the unique
and inherent HLA-binding properties of TCR-like antibodies, we have observed
low-affinity binding of 8F4 to HLA-A2 in other cell lines,40,50 and also observed
low background 8F4 staining in non-pulsed U266 cells. However, to highlight the
specificity of 8F4 for PR1/HLA-A2 complex, the HLA-A2- multiple myeloma cell
lines, OPM-2 and RPMI 8226 were also co-cultured with HLA-A2- PMN and
examined for cross-presentation (Figure 8). Thus, these data confirm NE and P3
internalization by U266 multiple myeloma cells. Notably, there were differences
in the magnitude of internalization between NE or P3 based on the protein
source: PMN-derived NE achieved higher intracellular levels than soluble NE and
was comparable to the uptake of PMN-derived P3.
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Figure 5. HLA-A2+ U266 cell line takes up NE and P3 from soluble and cellassociated sources.
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Figure 5. HLA-A2+ U266 cell line takes up NE and P3 from soluble and cellassociated sources. HLA-A2+ U266 multiple myeloma cell line was cultured
with soluble NE (10 μg/mL) or P3 (10 μg/mL) (A), or irradiated HLA-A2- PMN (B)
at the indicated time points. Cells were permeabilized, stained with anti-NE or
anti-P3 antibody and analyzed by flow cytometry. For cell-associated uptake,
light scatter and HLA-A2 staining seen on flow cytometry provided a clear
distinction between PMN and U266 cells. PMN alone were used as a positive
control for NE and P3 (white bars). ANOVA was performed using Prism 6.0
software (*P<0.05). Data are means ± SEM from triplicate experiments.
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Figure 6. NE and P3 localize within the cell following co-culture with U266
multiple cells.
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Figure 6. NE and P3 localize within the cell following co-culture with U266
multiple cells. HLA-A2+ U266 multiple myeloma cell line was cultured with
soluble NE (10 μg/mL) (A) or P3 (10 μg/mL) (B). Cells were either surface
stained or were permeabilized and then stained with anti-NE or anti-P3 antibody
and analyzed by flow cytometry to confirm uptake.
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Figure 7. HLA-A2+ U266 cell cross-presents NE and P3 from soluble and
cell-associated sources.
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Figure 7. HLA-A2+ U266 cell cross-presents NE and P3 from soluble and
cell-associated sources. U266 cells were cultured with soluble NE or P3 (10
μg/mL) (A) or irradiated PMN (B) then analyzed for expression of surface
PR1/HLA-A2 using 8F4-Alexa 647. Mean ± SEM fold increase of the median
fluorescence intensity (MFI) of PR1/HLA-A2 is shown from duplicate
experiments. Time “0” indicates untreated cells. ANOVA test was performed
using Prism 6.0 software (*P<0.05).
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Figure 8. Absence of PR1 cross-presentation in HLA-A2 negative multiple
myeloma cell lines.
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Figure 8. Absence of PR1 cross-presentation in HLA-A2 negative multiple
myeloma cell lines. HLA-A2 negative OPM-2 and RPMI 8226 multiple myeloma
cell lines were cultured with irradiated HLA-A2 negative PMN at the indicated
time points then analyzed for expression of surface PR1/HLA-A2 using 8F4-Alex
647. Mean ± SEM of the median fluorescence intensity (MFI) of PR1/HLA-A2 is
shown from a representative experiment that was performed in duplicate. Time
“0” indicates untreated cells. U937-A2+ cell line was used as a positive control for
PR1/HLA-A2.50 ANOVA test was performed using Prism 6.0 software. NS, not
significant.
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4.3 Cross-presentation by multiple myeloma involves the proteasome and
Golgi/ER.
Cross-presentation involves distinct, well-defined pathways that utilize the
proteasome and ER/Golgi.63-65 The proteasome plays an important role in
antigen cross-presentation by cleaving intracellular proteins into small, 8-11
amino acid peptides, which are transported into the ER by the TAP1/2 complex.
In the ER, peptides are loaded onto HLA class I molecules using components of
the antigen processing machinery and are then exported to the cell surface via
the Golgi. We hypothesized that NE and P3 cross-presentation involves
proteasome and ER/Golgi shuttling, as previously shown for NE and P3 crosspresentation by solid tumors and APCs.40,41 Our data confirm that multiple
myeloma utilizes the ER/Golgi and proteasome for NE and P3 crosspresentation, since incubation of cells with lactacystin, a proteasome inhibitor,
and brefeldin A, which inhibits ER to Golgi antegrade transport, both decreased
PR1/HLA-A2 expression (Figure 9A and B).
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Figure 9. Proteasome and ER/Golgi are involved in the cross-presentation
of NE and P3 by U266 multiple myeloma cells.
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Figure 9. Proteasome and ER/Golgi are involved in the cross-presentation
of NE and P3 by U266 multiple myeloma cells. U266 multiple myeloma cells
were cultured for 24 hours in media containing NE or P3 (10 μg/mL) and the
antigen processing machinery inhibitors lactacystin (proteasome inhibitor) or
brefeldin A (ER/Golgi transport inhibitor) (A, B). PBMC were cultured with U266
to serve as a negative control, since PBMC lack NE and P3. Cells were then
analyzed using flow cytometry for expression of PR1/HLA-A2 after surface
staining with 8F4-Alexa-647. Mean ± SEM of the median fluorescence intensity
(MFI) of PR1/HLA-A2 is shown from duplicate wells from 3 separate
experiments. ANOVA test was performed using Prism 6.0 software (*P<0.05).
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Next, we translated our in vitro studies into a clinically relevant system by
examining PMN as the source for NE and P3 and using bortezomib, a
proteasome inhibitor approved for treatment of multiple myeloma. In agreement
with our findings with lactacystin, bortezomib reduced PR1/HLA-A2 on the U266
myeloma cell surface (Figure 10). Additionally, the IMiD lenalidomide did not alter
surface levels of PR1/HLA-A2 on U266 after co-culture with PMN (Figure 11).
We also observed a consistent decrease in the surface expression of overall
HLA-A2 due to inhibition of the proteasome after treatment with both lactacystin
and bortezomib (Figure 12A and B). However, surface HLA-A2 expression was
unaffected by brefeldin A or lenalidomide (Figure 13A and B). Since conventional
antigen cross-presentation mechanisms employ proteasome,37 it is not surprising
that overall expression of HLA-A2 decreases with the use of lactacystin and
bortezomib, and highlights the role of the proteasome in PR1 cross-presentation.
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Figure 10. Bortezomib reduces PR1/HLA-A2 expression on the cell surface
of U266 multiple myeloma cells.
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Figure 10. Bortezomib reduces PR1/HLA-A2 expression on the cell surface
of U266 multiple myeloma cells. U266 multiple myeloma cells were cultured for
24 hours with PMN at a 1:1 U266:PMN ratio in media containing bortezomib
(Bor). PBMC were cultured with U266 to serve as a negative control, since
PBMC lack NE and P3. Cells were then analyzed using flow cytometry for
expression of PR1/HLA-A2 after surface staining with 8F4-Alexa-647. Mean ±
SEM of the median fluorescence intensity (MFI) of PR1/HLA-A2 is shown from
duplicate wells from 3 separate experiments. ANOVA test was performed using
Prism 6.0 software (*P<0.05).
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Figure 11. Lenalidomide does not reduce PR1/HLA-A2 expression on the
cell surface of U266 multiple myeloma cells.
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Figure 11. Lenalidomide does not reduce PR1/HLA-A2 expression on the
cell surface of U266 multiple myeloma cells. U266 multiple myeloma cells
were cultured for 24 hours with PMN at a 1:1 U266:PMN ratio in media
containing lenalidomide (Len). PBMC were cultured with U266 to serve as a
negative control, since PBMC lack NE and P3. Cells were then analyzed using
flow cytometry for expression of PR1/HLA-A2 after surface staining with 8F4Alexa-647. Mean ± SEM of the median fluorescence intensity (MFI) of PR1/HLAA2 is shown from duplicate wells from 3 separate experiments. ANOVA test was
performed using Prism 6.0 software. NS, not significant.
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Figure 12. HLA-A2 expression on U266 is reduced after addition of
proteasome inhibitors.
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Figure 12. HLA-A2 expression on U266 is reduced after addition of
proteasome inhibitors. U266 multiple myeloma cells were cultured for 24 hours
in media containing NE or P3 (10 μg/mL) and lactacystin (proteasome inhibitor)
(A) or were cultured for 24 hours with PMN at a 1:1 U266:PMN ratio in media
containing bortezomib (Bor) (B). Cells were then analyzed using flow cytometry
for expression of HLA-A2. Mean ± SEM of the median fluorescence intensity
(MFI) of HLA-A2 is shown from duplicate wells from 3 separate experiments.
ANOVA test was performed using Prism 6.0 software (**P<0.01, ***P<0.001).
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Figure 13. HLA-A2 expression on U266 is not reduced after addition of
brefeldin A or lenalidomide.
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Figure 13. HLA-A2 expression on U266 is not reduced after addition of
brefeldin A or lenalidomide. U266 multiple myeloma cells were cultured for 24
hours in media containing NE or P3 (10 μg/mL) and brefeldin A (ER/Golgi
transport inhibitor) (A) or were cultured for 24 hours with PMN at a 1:1
U266:PMN ratio in media containing lenalidomide (Len) (B). Cells were then
analyzed using flow cytometry for expression of HLA-A2. Mean ± SEM of the
median fluorescence intensity (MFI) of HLA-A2 is shown from duplicate wells
from 3 separate experiments. ANOVA test was performed using Prism 6.0
software. NS, not significant.
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4.4 PR1 cross-presentation by multiple myeloma is TAP-dependent
Since we previously demonstrated that PR1 cross-presentation utilizes the
proteasome and ER/Golgi, conventional components of antigen presentation, we
further investigated the role of the other antigen presentation machinery proteins
(APM). As discussed earlier in this work, cross-presentation can utilize TAP to
transport peptides from the cytosol into the ER for HLA loading. However, there
also are other described peptide loading mechanisms that are TAP-independent.
To characterize the role of TAP in multiple myeloma cross-presentation, we
knocked-down TAP expression in U266 cells by siRNA. si-TAP U266 cells were
then cultured in media supplemented with soluble NE to facilitate crosspresentation. Calcein-AM cytotoxicity assays show significant reduction in PR1CTL recognition at 5:1 E:T ratios. This indicates that si-TAP U266 cells pulsed
with NE were less susceptible to killing by PR1-CTL than si-control U266 cells
(Figure 14A). These data suggest that TAP is required for cross-presentation of
NE and PR1/HLA-A2 expression by U266. Sufficient TAP knock-down in U266
was confirmed by western blot (Figure 14B). Additionally, the total HLA
expression was unaffected by siRNA further suggesting these observations are
not due to global change in peptide HLA expression (Figure 14B).
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Figure 14. TAP knock-down in U266 results in decreased PR1/HLA-A2
expression and PR1-mediated killing.
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Figure 14. TAP knock-down in U266 results in decreased PR1/HLA-A2
expression and PR1-mediated killing. (A) TAP1 was knocked-down in U266
cells using siRNA for TAP1. After 48 hours, U266 cells we cultured with or
without soluble NE (10µg/mL) supplemented media for 24 hours. Calcein AM
cytotoxicity assays using PR1-specific CTL were then performed at varying
effetor:target (E:T) ratios. Significantly higher killing of target cells was seen at
the 5:1 E:T ratios for the si-control U266 +NE group compared to both si-TAP1
U266+NE and si-control U266 untreated group. (*P<0.05). Statistical analysis
was performed using ANOVA test. (B) Western blot analysis confirms sufficient
knock-down of TAP1 was achieved in U266 cells when treated with si-TAP1.
GAPDH was used as a loading control.
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Additionally, we sought to investigate whether the other APM proteins
were differentially expressed in multiple myeloma patients. To this end, we
analyzed the expression of the core components of the APM: calnexin, TAP,
tapasin, LMP2/7 in patient multiple myeloma cells using western blot (Figure 15).
Expression among the APM proteins, LMP7, LMP2, and tapasin were shown to
be upregulated in multiple myeloma patients when compared to healthy donor B
cells. We did not observe protein expression differences in the other APM
components, calnexin and HLA. However, we did observe a lower expressed
isoform of calnexin in Patient 3 who also showed decreased HLA expression. We
further investigated the expression of calnexin and HLA among 10 other multiple
myeloma patients by western blot (Figure 16). Our data show that two prominent
isoforms of calnexin are expressed in multiple myeloma patient cells and this is
correlated with lower HLA expression in patients that express the lower
molecular weight isoform of calnexin. Interestingly, the lower HLA expression
pattern observed in these multiple myeloma patients resembled a similar doubleband phenotype of immature HLA molecules when retained in the ER.66 This
expression pattern may suggest a potential dominant negative effect mediated
through improper chaperone functions by an alternative calnexin isoform where
immature HLA molecules are retained in the ER and prevented from proper
folding and egress to the cell surface.
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Figure 15. APM proteins LMP7, LMP2, and tapasin are upregulated in
multiple myeloma patients.
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Figure 15. APM proteins LMP7, LMP2, and tapasin are upregulated in
multiple myeloma patients. The expression of the major proteins that comprise
the antigen presentation machinery (APM) were analyzed via western blotting.
Whole cell lysates were generated from CD138+ enriched cells from the bone
marrow of newly diagnosed multiple myeloma patients. B cells sorted from
healthy donor peripheral blood monocytes were used as a control for nonmalignant protein expression levels. Patient whole cell lysates were loaded and
separated by gel electrophoresis under reducing conditions. β-actin was used as
a loading control. Expression among the APM proteins and across patients
appears variable, with expression observed to be upregulated in some proteins
(LMP7, LMP2, Tapasin) or unchanged (HLA, Calnexin).
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Figure 16. Multiple myeloma patients express different isoforms of
calnexin.
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Figure 16. Multiple myeloma patients express different isoforms of
calnexin. Whole cell protein lysates were generated from CD138+ cells of 10
newly diagnosed multiple myeloma patients as previously described in Figure 15.
Western blotting was performed using antibodies against calnexin, HLA-ABC and
β-actin as a loading control. Western blot analysis indicates two isoforms of
calnexin expressed in multiple myeloma patients, with the lower molecular weight
isoform correlating to a decreased expression of Pan-HLA.
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4.5 Chapter 4 Summary
Collectively our data demonstrates that multiple myeloma is capable of
cross-presenting exogenous antigens. We have modeled this phenomenon by
tracking the expression of two myeloid-restricted serine proteases, NE and P3.
Multiple myeloma cells do not endogenously express NE or P3, but are capable
of taking up these proteins from the extracellular environment and internalizing
them in the cytoplasm. Furthermore, NE and P3 can be processed in a
proteasome-dependent manner, leading to the expression of the PR1 antigen in
the context of HLA-A2 on the multiple myeloma cell surface.

Importantly, multiple myeloma relies on the proteasome for effective
cross-presentation of NE and P3, as use of proteasome inhibitors, lactacystin
and bortezomib, muted the expression of PR1/HLA-A2 in U266 multiple myeloma
cells. Additionally, use of Golgi transport inhibitor, brefeldin A, revealed that
multiple myeloma cross-presentation also relies on the canonical ER to Golgi
shuttling pathway for PR1/HLA-A2 surface expression. Our data also supports a
TAP-dependent mechanism for PR1 cross-presentation as silencing TAP in
U266 resulted in decreased PR1/HLA-A2 and PR1-CTL recognition. Treatment
with the IMiD lenalidomide did not affect the ability of U266 cells to cross-present
NE and P3 as there was no observed decrease in PR1/HLA-A2 expression.

Overall our data thus far have revealed a unique mechanism by which
multiple myeloma cells can express a novel antigen, PR1, via cross-presentation.
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Chapter 5: Evaluate the susceptibility of multiple myeloma to
PR1-targeting immunotherapies
The following chapter is based on my publication, used with permission granted
by AACR Journals.
Alatrash, G.1, Perakis, A.A.1, Kerros, C., Peters, H.L., Sukhumalchandra, P.,
Zhang, M., Jakher, H., Zope, M., Patenia, R., Sergeeva, A., Yi, S., Young, K.H.,
Philips, A.V., Cernosek, A.M., Garber, H.R., Qiao, N., Weng, J., St John, L.S.,
Lu, S., Clise-Dwyer, K., Mittendorf, E.A., Ma, Q. & Molldrem, J.J. Targeting the
Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple
Myeloma. Clin Cancer Res 24, 3386-3396 (2018).

5.1 PR1 cross-presentation increases the susceptibility of multiple
myeloma to PR1-CTL and 8F4 antibody
Immunotherapy targeting PR1 has shown promising efficacy in the
treatment of myeloid malignancies.49,50,67,68 Thus, we investigated whether PR1
cross-presentation by multiple myeloma cells could lead to their lysis by PR1CTL and the complement-fixing, anti-PR1/HLA-A2 8F4 antibody. Calcein-AM
cytotoxicity assays demonstrate that cross-presentation of NE and P3 by U266
cells renders them susceptible to killing by PR1-CTL and 8F4 antibody in a dosedependent manner (Figure 17). Specifically, NE enhanced the killing of U266
cells by PR1-CTL at 10:1 and 5:1 effector: target (E:T) ratios, when compared to
untreated or ova-supplemented U266 cells (Figure 17A). The efficacy of PR1CTL in eliminating PR1-cross-presenting multiple myeloma cells was further
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validated by U266 cells that were supplemented with P3, where killing was
demonstrated at the 10:1, 5:1 and 2.5:1 E:T ratios (Figure 17A).

Since we have previously shown that the anti-PR1/HLA-A2 antibody (8F4)
lyses malignant cells via CDC,40,50 we tested whether multiple myeloma could be
killed by 8F4. In a standard CDC assay, we demonstrate significantly higher 8F4mediated killing of U266 target cells that were cultured with NE and P3 (Figure
17B). Combined, these studies show that multiple myeloma is rendered
susceptible to killing by PR1-targeting immunotherapies and further confirm PR1
cross-presentation by multiple myeloma.
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Figure 17. PR1 cross-presentation increases the susceptibility of multiple
myeloma to PR1-CTL and anti-PR1/HLA-A2 antibody.
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Figure 17. PR1 cross-presentation increases the susceptibility of multiple
myeloma to PR1-CTL and anti-PR1/HLA-A2 antibody. (A) When comparing
PR1-CTL killing of target U266 cells supplemented with NE or P3 to ovasupplemented U266 and U266 cells alone, significantly higher killing of target
cells was seen at the 10:1 and 5:1 E:T ratios for the U266 + NE group and 10:1,
5:1 and 2.5:1 E:T ratios for the U266 + P3 group (*P<0.05). (B) Similarly, when
comparing 8F4 killing of NE-supplemented and P3-supplemented U266 target
cells to ova-supplemented U266 and U266 cells alone, significantly higher killing
of target cells was seen at the 10 μg/mL and 5 μg/mL 8F4 concentrations for the
NE-supplemented group and at the 10 μg/mL, 5 μg/mL and 2.5 μg/mL 8F4
concentrations for the P3-supplemented group (*P<0.05). Significantly higher
killing was also demonstrated when comparing P3-supplemented U266 to ovasupplemented U266 at the 1.25 μg/mL 8F4 concentration. Statistical analysis
was performed using ANOVA test.
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5.2 PR1-CTL and 8F4 antibody reduce multiple myeloma burden in
xenograft mice
Since PR1 cross-presentation by U266 increases susceptibility to PR1
targeting immunotherapy in vitro, we next investigated whether PR1 can be
targeted in vivo using a multiple myeloma U266 xenograft mouse model.54 To
test this hypothesis, we utilized NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice,
which contain bone marrow resident PMN, providing an available source of NE
and P3 for cross-presentation. Additionally, the murine PR1 sequence is
homologous to the human sequence (VLQELNVTV), and murine CTL can
recognize PR1/HLA-A2 and are able to be expanded after vaccination.69 In this
xenograft model, GFP and luciferase transduced U266 cells home to various
bone marrow tissues such as the tibia, fibula, spine, and skull of NSG mice within
two weeks of engraftment. Multiple myeloma progression can be monitored by
IgE ELISA, as U266 is an IgE secreting multiple myeloma subtype, and by
bioluminescent imaging (BLI, Figure 18).

After confirming U266 engraftment in the bone marrow and following
treatment with 8F4, we demonstrate a significantly decreased U266 multiple
myeloma burden, as shown by a decrease in the concentration of human IgE in
mouse serum in comparison with isotype and untreated groups (Figure 19A).
Furthermore, 8F4 treatment also noticeably reduced the percent of multiple
myeloma cells in mouse bone marrow in comparison to mice treated with isotype
and untreated mice (Figure 19B). Similar results were also seen using PR1-CTL
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(Figure 19C). U266 multiple myeloma cells were identified as human CD45+ and
mouse CD45- cells (Figure 20A and B). Additionally, BLI measurements
corroborated these findings (Figure 21). We also observed significant prolonged
survival in mice treated with 8F4 compared to mice that received isotype
antibody (Figure 22). Together, these data suggest that 8F4 and PR1-CTL are a
feasible and effective therapy for HLA-A2+ multiple myeloma.
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Figure 18. U266 multiple myeloma xenograft model and 8F4 treatment
schema.
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Figure 18. U266 multiple myeloma xenograft model and 8F4 treatment
schema. (A) Starting on day 0, female NSG mice were sub-lethally irradiated
(250 cGy) prior to U266 engraftment. After 24 hours, on day 1, NSG mice were
engrafted with 2 x 106 U266 cells via tail vein injection. Engraftment was
monitored and confirmed on days 14-21 by both IgE ELISA and bioluminescent
imaging (BLI, IVIS100). Mice were then received 10 total injections over 21 days
of 8F4 antibody or IgG isotype control (Herceptin). Disease progression and
treatment effects were monitored by ELISA and BLI. Mice were sacrificed and
bone marrow harvested by day 56. (B) Human IgE concentrations in mouse
serum were analyzed by ELISA. Mice that were engrafted with U266 cells show
increasing accumulation of human IgE over time compared to mice who were
unengrafted. (C) U266 cells recovered from mouse bone marrow can be
identified from mouse bone marrow by mouse CD45 (mCD45)-negative, human
CD45 (hCD45)-positive, human CD138 (hCD138)-positive, or HLA-A2-positive
staining.
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Figure 19. 8F4 antibody and PR1-CTL reduce multiple myeloma in U266
xenograft mice.
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Figure 19. 8F4 antibody and PR1-CTL reduce multiple myeloma in U266
xenograft mice. U266 multiple myeloma xenograft mice were established and
treated with (A, B) 8F4 antibody, IgG isotype control, or (C) PR1-CTL. (A) Mouse
serum was collected by tail bleeding and separated by centrifugation. Human IgE
was measured using ELISA. 8F4 treated mice show reduced circulating human
IgE levels compared to isotype and untreated mice (****P<0.0001). (B) At the
end of treatment mice were sacrificed and bone marrow was harvested, a single
cell suspension of bone marrow was generated and analyzed by flow cytometry
for residual U266 cells. 8F4 treated mice show reduced percentage of U266 cells
in the bone marrow compared to isotype and untreated mice (****P<0.0001).
Percent of myeloma cells were normalized to untreated mouse bone marrow for
each experiment. (C) Mouse bone marrow was analyzed by flow cytometry after
treatment with PR1-CTL. PR1-CTL-treated mice show reduced percentage of
U266 cells in the bone marrow compared to mice treated with irrelevant peptideCTL (**P<0.01) or untreated mice (***P<0.001). Statistical analysis was
performed using ANOVA test.
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Figure 20. Gating strategy for identifying U266 cells in mouse bone marrow.
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Figure 20. Gating strategy for identifying U266 cells in mouse bone marrow.
Gating strategy utilized to identify U266 cells in mouse bone marrow. U266 cells
were defined as human CD45+ mouse CD45-. Bone marrow of a representative
mouse that was untreated (A, PBS) shows a robust multiple myeloma burden
compared to the bone marrow of an 8F4 treated mouse (B).
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Figure 21. 8F4 antibody impedes multiple myeloma growth in U266
xenograft mice.

A

8F4

Isotype

B
1.50×1010
****

1.00×1010
7.50×109
5.00×109
2.50×109

pe

4

0.00
Is
ot
y

8F

Total flux (p/s)

1.25×1010

73

Figure 21. 8F4 antibody impedes multiple myeloma growth in U266
xenograft mice. 8F4 antibody treatment reduced multiple myeloma burden and
growth. BLI images were captured using an IVIS 100 at the Small Animal
Imaging Facility at MD Anderson Cancer center. Bioluminescent images were
analyzed using Living Image software (PerkinElmer). All images were set to the
same scale before analysis. (A) Representative images of mice treated with
either 8F4 antibody or isotype control. (B) BLI images were quantified by
measuring total flux (p/s) from ventral images of mice treated with 8F4 antibody
or isotype control. 8F4 treated mice showed reduced multiple myeloma growth
compared to isotype treated mice (****P<0.0001). Statistical analysis was
performed using two-tailed T test.
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Figure 22. 8F4 antibody extends survival in U266 xenograft mice
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Figure 22. 8F4 antibody extends survival in U266 xenograft mice. U266
xenograft mice were established and treated as previously described in Figure 18
and Figure 19. Time of death for each animal was determined when the mouse
became moribund. Kaplan-Meier curves show longer median survival for mice
treated with 8F4 antibody (median 99 days, n=10) compared to mice that
received IgG isotype control antibody (Herceptin; median 77 days, n=20)
(****P<0.0001).
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5.3 8F4 antibody and bortezomib combination therapy results in an
increased anti-myeloma effect
As combination therapy for multiple myeloma is commonplace already,
and new multiple myeloma therapies are frequently being used in combination,
we aimed to further our understanding of how 8F4 could be integrated into
standard of care treatments. To this end, we sought to investigate the interaction
between 8F4 and bortezomib and identify any potential cooperative effects for
treating multiple myeloma. First we observed an additive anti-myeloma effect
when 8F4 is combined with bortezomib using an Annexin V flow-based apoptosis
assay in vitro (Figure 23). Greater cell death was noted in U266 cells that were
co-cultured with PMN and received combination therapy compared to cells that
received either 8F4 or bortezomib single agent therapy alone.

Furthermore, we translated our findings using our U266 xenograft model
and found that combination therapy of 8F4 and bortezomib more effectively
reduces the myeloma burden in xenograft mice as well as prolongs survival
(Figure 24). As multiple myeloma therapies continue to improve, we also
investigated whether improved beneficiary effects could be achieved with nextgeneration proteasome inhibitors, such as carfilzomib. While not significant at
this time, mice that received 8F4 in combination with carfilzomib appear to have
a longer survival rate than those that received bortezomib (Figure 24B).
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Figure 23. 8F4 and bortezomib combination has additive anti-myeloma

activity.
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Figure 23. 8F4 and bortezomib combination has an additive anti-myeloma
activity. U266 cells were co-cultured with irradiated PMN 24 hours prior to drug
exposure to facilitate PR1 cross-presentation (U266 +PMN) or unpulsed as
control. U937-WT and U937-A2 AML cell lines were used as negative and
positive controls for 8F4 mediated lysis respectively. U266 + PMN cells that
received 8F4 and bortezomib combination therapy showed increased apoptosis
via Annexin V and propidium iodide staining compared to U266 + PMN cells that
received 8F4 alone (***P<0.001) or bortezomib alone (***P<0.001). Mean ± SEM
of the sum percent of Annexin V+ and Annexin V+ propidium iodide+ is shown
from triplicate wells. Figure is representative of three independent experiments.
Statistical analysis was performed using ANOVA test. NS, not significant.
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Figure 24. 8F4 and bortezomib combination therapy more effectively
reduces the multiple myeloma burden in xenograft mice and prolongs
survival.
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Figure 24. 8F4 and bortezomib combination therapy more effectively
reduces the multiple myeloma burden in xenograft mice and prolongs
survival. U266 xenograft mice were established as previously described in
Figure 18 and Figure 19. (A) Mice were treated with low dose 8F4 antibody (0.05
mg/kg) alone or in combination with bortezomib (Bor, 0.025 mg/kg) or isotype
control antibody (1 mg/kg) alone or in combination with bortezomib (0.025
mg/kg). Combination therapy of 8F4 and bortezomib showed improved reduction
in human IgE serum levels in mice compared to those that received single agent
treatment of 8F4 (*P<0.05) and single agent treatment of bortezomib (**P<0.01).
Statistical analysis was performed using ANOVA test. (B) Prolonged survival was
measured up to 120 days in xenograft mice that received combination therapy.
Mice were treated with 8F4 antibody (10 mg/kg) alone or in combination with
bortezomib (0.025 mg/kg). Mice were also treated with 8F4 in combination with
next generation proteasome inhibitor, carfilzomib (Car, 0.025 mg/kg)
respectively. Time of death for each animal was determined when the mouse
became moribund. Kaplan-Meier curves show longer median survival for mice
treated with 8F4 antibody in combination with bortezomib (median 111.5 days,
n=5, *P<0.05) or carfilzomib (median undefined, n=5, **P<0.01) compared to
mice that received 8F4 antibody alone (median 96 days, n=5).
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5.4 PR1/HLA-A2 and PR1-CTL are detected in multiple myeloma patients
We next investigated whether PR1 could be detected in the bone marrow
(BM) from patients with multiple myeloma, and if immunity to PR1 (i.e., PR1-CTL)
could be detected in peripheral blood (PB) from patients with multiple myeloma
following allo-SCT. We were able to detect PR1/HLA-A2 on the surface of 4 of 8
HLA-A2+ patients with multiple myeloma (Table 1; Figure 25). To highlight the
low background staining and high specificity for the PR1/HLA-A2 combined
epitope of the 8F4 antibody, control staining and confocal imaging is was
performed on U266 cells pulsed or non pulsed with PMN (Figure 26).
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Table 1. Confocal imaging of PR1/HLA-A2 in multiple myeloma patients.

Patient

MM
subtype

UPN1

IgA
lambda
IgG
lambda
IgG
kappa
IgG
lambda
IgA
kappa
IgG
kappa
IgG
lambda
IgA
kappa

UPN2
UPN3
UPN4
UPN5
UPN6
UPN7
UPN8

Durie
Salmon
Stage
Stage II

Cytogenetics

Number of
treatments*

Normal diploid

History of
relapse or
progression
Yes

6

PR1/HLAA2
reactivity
-

Stage II

Del 13

Yes

6

-

Stage I

Normal diploid

Yes

4

-

Stage III

Del 17p13

Yes

1

-

Stage II

Del 13

Yes

0

+

Stage III

Normal diploid

Yes

0

+

Stage III

Del 13; t(4;14)

Yes

1

+

Stage II

Del 13; Del
17p13

Yes

5

+

*Number of treatments prior to sample acquisition.
Abbreviations: UPN, unique patient number; MM, multiple myeloma; Del,
deletion; N/A, not available; t, translocation.
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Figure 25. PR1/HLA-A2 is presented on the surface of patient multiple
myeloma cells.

A

B

Figure 25. PR1/HLA-A2 is presented on the surface of patient multiple
myeloma cells. Bone marrow smears from 2 patients with multiple myeloma
were stained with (A) anti-PR1/HLA-A2 (8F4)-647 (red) and anti-HLA-A2-Alex488 (green) or (B) anti-PR1/HLA-A2 (8F4)-647 (red) and anti-CD138-Alex-488
(green) and then imaged using confocal laser microscopy. PR1/HLA-A2 is
expressed by multiple myeloma cells as shown by the co-staining of 8F4 with
HLA-A2 or CD138.
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Figure 26. U266 cross-presents PR1 after exposure to NE/P3 from PMN coculture.
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Figure 26. U266 cross-presents PR1 after exposure to NE/P3 from PMN coculture.
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Figure 26. U266 cross-presents PR1 after exposure to NE/P3 from PMN coculture. Control staining of U266 cell line (A) co-cultured with PMN or (B)
untreated was evaluated by confocal microscopy. Immunofluorescence staining
for Alexa 647-8F4 (red), FITC-HLA-A2 (green) and DAPI stained nuclei (blue) is
shown. Data are representative images from three independent experiments.
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To determine whether PR1-CTL could be detected in PB from HLA-A2+
patients with multiple myeloma, we used PR1/HLA-A2 dextramer staining and
showed PR1-CTL in the PB from 10 of 14 multiple myeloma patients who
received allo-SCT (Table 2; Figure 27 and Figure 28). The median frequency of
PR1-CTL in these multiple myeloma patients was 0.053% of CD8+ T cells
(Range, 0%-1.67%), which is higher than the frequency of PR1-CTL reported in
HLA-A2+ healthy donors.70
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Table 2. PR1-CTL frequency in HLA-A2+ multiple myeloma patients
following allogeneic stem cell transplantation.
Patient

MM subtype

Days post
allo-SCT

Alive status

% dextramer staining

UPN4
UPN8
UPN9
UPN10
UPN11
UPN12
UPN13
UPN14
UPN15
UPN16
UPN17
UPN18
UPN19
UPN20

IgG lambda
IgA kappa
IgG lambda
Unspecified
Lambda light chain
IgG kappa
IgG kappa
IgA lambda
Kappa light chain
Kappa light chain
IgG kappa
IgG kappa
IgA lambda
IgA kappa

716
378
490
1089
97
266
197
247
176
77
379
93
718
163

No
No
No
No
Yes
Yes
Yes
Yes
No
No
No
No
Yes
No

0.00282
0.125
0.0192
0.002
0.255
0.231
1.668
0.088
0.0867
0
0
0
0.681
0

Abbreviations: UPN, unique patient number; MM, multiple myeloma; allo-SCT,
allogeneic stem cell transplantation
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Figure 27. Gating strategy used to determine PR1-CTL frequency in
peripheral blood of multiple myeloma patients following allogeneic stem
cell transplantation.
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Figure 27. Gating strategy used to determine PR1-CTL frequency in
peripheral blood of multiple myeloma patients following allogeneic stem
cell transplantation. Cells were stained with CD3, CD8 and PR1/HLA-A2dextramer and the lineage (Lin) markers CD4, CD14, CD16 and CD19. The
frequency of PR1/HLA-A2 dextramer+ cells (i.e. PR1-CTL) was determined as
the percent of cells from live, Lin-, CD3+, CD8+ cells.
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Figure 28. PR1 dextramer plots of multiple myeloma patients following
allogeneic stem cell transplantation.
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Figure 28. PR1 dextramer plots of multiple myeloma patients following
allogeneic stem cell transplantation. Four dextramer plots are representative
of the 14 multiple myeloma patients analyzed are shown. Bottom plots
represents the FMO staining control for the respective patient plot above. Cells
were stained with CD3, CD8 and PR1/HLA-A2-dextramer and the lineage (Lin)
markers CD4, CD14, CD16 and CD19. The frequency of PR1/HLA-A2
dextramer+ cells (i.e. PR1-CTL) was determined as the percent of cells from live,
Lin-, CD3+, CD8+ cells.
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Furthermore, using CD45RA and CCR7 staining, PR1-CTL phenotype
was analyzed in 4 of the patients and demonstrated primarily an effector memory
phenotype of the PR1-CTL (Figure 29). Additionally, we investigated whether
PR1-CTL are present in the PB of HLA-A2+ multiple myeloma patients after
receiving autologous stem cell transplant (auto-SCT) (Table 3; Figure 30). PR1CTL frequencies were detected by PR1/HLA-A2 tetramer staining in all 18
multiple myeloma patients following auto-SCT. The median frequency of PR1CTL in these patients was 0.205% (Range, 0.076%-1.31%). These patient data
suggest that bone marrow-derived NE and P3 is taken up and cross-presented
by multiple myeloma, and that immunity to PR1 is elicited in multiple myeloma
patients following SCT.
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CD45RA

Figure 29. Phenotype of PR1-CTL in patients following allo-SCT.

UPN 4

UPN 8

UPN 13

UPN 14

CCR7

Figure 29. Phenotype of PR1-CTL in patients following allo-SCT. Four
multiple myeloma patient samples were stained for PR1-CTL using PR1/HLA-A2
tetramer. Analysis of CCR7 and CD45RA surface expression was performed
after gating on the PR1/HLA-A2 dextramer-positive cell population (i.e., PR1CTL). Cells were classified based on the following staining pattern: central
memory (CCR7+/CD45RA-), effector memory (CCR7-/CD45RA-), naïve
(CCR7+/CD45RA+) or terminally differentiated (CCR7-/CD45RA+).
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Table 3. PR1-CTL frequency in HLA-A2+ multiple myeloma patients
following autologous stem cell transplantation.

Patient

MM subtype

UPN21
UPN22
UPN23
UPN24
UPN25
UPN26
UPN27
UPN28
UPN29
UPN30
UPN31
UPN32
UPN33
UPN34
UPN35
UPN36
UPN37
UPN38

IgG kappa
IgG kappa
IgG kappa
IgG kappa
IgG kappa
IgG kappa
IgA kappa
IgG kappa
IgG lambda
Lambda light chain
Kappa light chain
IgG lambda
IgG lambda
IgG kappa
IgA kappa
IgG kappa
IgG kappa
IgG kappa

Days post
auto-SCT
98
154
170
260
1895
32
454
36
962
104
392
353
367
301
274
375
351
304

Alive status
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

% PR1 tetramer
staining
0.24
0.22
0.29
0.25
0.12
0.21
0.081
0.12
0.098
0.076
1.31
0.28
0.4
0.12
0.13
0.16
0.2
0.48

Abbreviations: UPN, unique patient number; MM, multiple myeloma; auto-SCT,
autologous stem cell transplantation
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Figure 30. Gating Strategy used to determine PR1-CTL frequency in
peripheral blood of multiple myeloma patients following autologous stem
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Figure 30. Gating Strategy used to determine PR1-CTL frequency in
peripheral blood of multiple myeloma patients following autologous stem
cell transplantation. Cells were stained with CD3, CD8 and PR1/HLA-A2tetramer and the lineage (Lin) markers CD4, CD14, CD16 and CD19. The
frequency of PR1/HLA-A2 tetramer+ cells (i.e. PR1-CTL) was determined as the
percent of cells from live, Lin-, CD3+, CD8+ cells.
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Lastly, we used flow cytometry to study the expression of PR1 on CD138+
multiple myeloma cells from patient bone marrow (to corroborate confocal
microscopy data [Table 1; Figure 25]) and to also investigate the expression of
co-stimulatory molecules on PR1/CD138+ multiple myeloma cells. Our data
show surface expression of PR1 and co-stimulatory molecules HLA-DR, CD40,
CD80 and CD86 on CD138+ multiple myeloma cells in 12 out of 12 total patients
(Table 4; Figure 31), further supporting the observation that patient multiple
myeloma cells are capable of PR1 cross-presentation, and possibly crosspriming.
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Table 4. Co-stimulatory molecule expression of PR1/HLA-A2+ multiple
myeloma patients.

CD138+

Cell surface markers on CD138+8F4+
subpopulation

Patient

%8F4+
subset

%HLA-DR+
MFI

UPN39

22.6%

64.1%
2327

UPN40

45.1%

UPN41

% CD80+
MFI

% CD86+
MFI

3.40%
407

14.6%
1672

37.9%
1888

64.4%
2216

2.32%
386

2.41%
1189

19.1%
1883

32.3%

42.3%
1433

0.095%
407

0.99%
1024

6.05%
1463

UPN42

54.0%

37.8%
1654

0.074%
308

3.22%
1164

12.8%
1653

UPN43

79.1%

25.0%
1275

1.04%
358

1.48%
1041

18.7%
1634

UPN44

73.4%

45.4%
1325

0.013%
362

0.54%
1067

4.71%
1417

UPN45

56.9%

47.0%
1451

0.20%
400

0.46%
1105

21.8%
1719

UPN46

84.1%

61.4%
1966

0.014%
312

1.23%
962

26.4%
1695

UPN47

67.6%

64.6%
2376

0.075%
359

4.05%
1301

21.7%
1960

UPN48

59.6%

23.3%
2216

0.079%
331

0.69%
1159

9.77%
1703

UPN49

73.2%

14.7%
1551

2.29%
421

0.078%
1007

7.85%
1664

UPN50

76.7%

17.4%
789

4.35%
402

4.35%
1076

4.35%
1388

H2023 lung
cancer

N/A

N/A
224

N/A
127

N/A
178

N/A
140

T-47D breast
cancer

N/A

N/A
73

N/A
0

N/A
16

N/A
0

MDA-MB-453
breast cancer

N/A

N/A
198

N/A
0

N/A
68

N/A
176
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%CD40+
MFI

Table 4. Co-stimulatory molecule expression of PR1/HLA-A2+ multiple
myeloma patients.
Abbreviations: UPN, unique patient number; MFI, median fluorescence intensity;
N/A, not applicable. H2023 lung cancer, T-47D breast cancer, MDA-BM-453
breast cancer cell lines used as negative controls.
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Figure 31. Gating Strategy used to determine PR1 expression and costimulatory molecule expression on patient bone marrow multiple myeloma
cells.
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Figure 31. Gating Strategy used to determine PR1 expression and costimulatory molecule expression on patient bone marrow multiple myeloma
cells. Cells were stained with CD19, CD33, CD34, CD38, CD138, and HLAA2/PR1 antibody (8F4) to identify PR1 expressing multiple myeloma cells.
Analysis of surface expression for CD40, CD80, CD86, and HLA-DR was
performed after gating on the PR1/HLA-A2 and CD138 double positive cell
population.
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5.5 Chapter 5 Summary

This work illustrates that cross-presented antigens can be effectively
targeted using immunotherapy in the setting of multiple myeloma. We have
demonstrated that multiple myeloma can cross-present PR1, and consequently
be targeted using PR1-targeting immunotherapy using PR1-CTL and the 8F4
antibody in vitro and in vivo. Utilizing in vitro cytotoxicity assays, U266 were
eliminated after being cultured in media supplemented with soluble NE or P3 by
PR1-CTL and 8F4 antibody. Additionally, we utilized a multiple myeloma
xenograft mouse model, which illustrated that PR1-CTL and 8F4 antibody
treatment can drastically reduce the multiple myeloma burden in mice and extend
animal survival.

Additionally, we observed the presence of PR1-CTL in the peripheral
blood and bone marrow of multiple myeloma patients. PR1-CTL were detected in
the peripheral blood of patients after allo- and auto-SCT and were primarily
observed to be effector memory cells. Collectively, this suggests that there is the
potential to elicit immunity against PR1 in multiple myeloma patients. Our data
also indicate that PR1-expressing multiple myeloma cells from patients express
the co-stimulatory molecules HLA-DR, CD40, CD80, and CD86. This finding
suggests that multiple myeloma cells could be capable of cross-priming, a
potential ancestral role from their B cell origin.
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Overall our work has illustrated that cross-presentation of PR1 renders
multiple myeloma susceptible to PR1-targeting immunotherapies.

101

Chapter 6: Discussion
In summary, our work demonstrates the novel ability for multiple myeloma
cells to take up and cross-present NE and P3. Multiple myeloma cells lack
endogenous NE and P3 expression but possess the ability to internalize these
proteins from soluble or cell-associated sources. This internalization leads to the
processing of NE and P3 by the proteasome and the subsequent loading of PR1
peptide onto HLA-A2 molecules in a TAP-dependent manner. This process
ultimately results in PR1/HLA-A2 expression by multiple myeloma through crosspresentation. Consequently, PR1 cross-presentation leads to the ability to target
and eliminate multiple myeloma cells by PR1-targeting immunotherapies such as
PR1-CTL or 8F4 antibody (Figure 32). Overall, our work has identified crosspresentation as a novel mechanism by which multiple myeloma expresses tumor
antigens and underlines the therapeutic potential of PR1-targeting
immunotherapies for the treatment of multiple myeloma. This suggests that the
antigen landscape in myeloma is broader than previously believed. This newly
appreciated and expanded antigen repertoire may lead to the discovery of a new
class of multiple myeloma antigens and the development of new
immunotherapies.

The antigenic library of multiple myeloma is rapidly expanding. As briefly
mentioned in the introduction of this dissertation, there have been several recent
and promising antigens being investigated for the targeting multiple myeloma
(CD38, SLAMF7, BCMA). New approaches using immunoprecipitation and mass
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spectrometry are further expanding the potential antigenic profile of multiple
myeloma.71 However, these endeavors have focused primarily on endogenous
peptides and to date have not considered cross-presented peptides as potential
immunotherapeutic targets. Our work further expands the potential antigenic
repertoire of multiple myeloma, illustrated by the ability to target a crosspresented myeloid leukemia antigen, PR1.

Cross-presentation is an important link between the innate and adaptive
immune response. Defects in cross-presentation results in the inability to mount
a proper CD8+ T cell response against exogenous antigens from viral or tumor
sources.72,73 Classically, B cells are considered to have cross-presentation
capabilities; being able to cross-present antigens and prime CD8+ T cells.74,75
Additionally, plasma cells have also been implicated in priming T cells via crosspresentation.76 Our work here is the first to reveal that multiple myeloma is
capable of antigen cross-presentation. Interestingly, studies have shown CD38+
plasma cells in multiple myeloma patients expressed a range of co-stimulatory
molecules (CD40, CD80, CD86, HLA-DR), although at low levels.76,77 In one
specific study, Pérez-Andrés and colleagues observed a progressive decrease in
the co-stimulatory capacity in malignant plasma cells from MGUS to multiple
myeloma.77 These observations are corroborated by our own data, which show a
small subset of multiple myeloma cells express these co-stimulatory molecules
on the cell surface. Together, these data suggest that there may exist
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immunological scenarios where multiple myeloma could function as an APC and
prime a CD8+ T cell response.

The proteasome plays a prominent role in both antigen presentation and
cross-presentation. Our work highlights the importance of the proteasome in PR1
cross-presentation by multiple myeloma. When multiple myeloma cells were
treated with the proteasome inhibitors, lactacystin or bortezomib, a significant
reduction in cross-presentation of NE and P3 was observed, noted by the
decrease in PR1/HLA-A2 surface expression. The role of the proteasome in
cross-presentation by multiple myeloma is particularly important in the context of
bortezomib; a front line therapy administered to newly diagnosed myeloma
patients.

Currently, the precise effects of bortezomib and proteasome inhibition on
multiple myeloma have yet to be fully elucidated. In our investigations, treating
multiple myeloma cells with bortezomib in vitro resulted in decreased PR1 crosspresentation and global HLA-A2 surface expression. However, others have
shown that following bortezomib treatment, an increase in antigen presentation
was observed.78,79 Proteins can be processed by various mechanisms,
specifically through cytoplasmic or lysosomal peptidases, bypassing the
proteasome. Potentially NE and P3 could also be processed by these peptidases
or loaded through the alternative vacuolar pathway, leading to PR1 crosspresentation even in the context of proteasome inhibition. Our own findings have
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also challenged the idea that proteasome inhibition is damaging to antigen
presentation. Our in vivo studies, where combination 8F4 antibody and
bortezomib were administered to U266 xenograft mice resulted in a more potent
anti-myeloma effect by extending animal survival in the U266 xenograft model.
Furthermore, when we investigated this cooperative anti-myeloma effect in vitro
using flow cytometry based apoptosis assays, we also observed increased cell
death when both drugs were used in combination. Since this contradicts our data
showing that proteasome inhibition decrease PR1/HLA-A2 expression on the cell
surface in vitro, we hypothesize that bortezomib could be suppressing global
antigen presentation in multiple myeloma, potentially reducing the background
peptide noise on the myeloma cell surface. This could allow for an enrichment of
PR1/HLA-A2 expression for targeting by 8F4 antibody. Also, the enhanced killing
of multiple myeloma by the combination of 8F4 and bortezomib may be due to
mechanisms unique to 8F4, whereby proteasome inhibition could potentiate the
direct mechanism of action of 8F4; this work is currently being investigated by
our group.

The proteasome is inherently complex. Studies have even reported that
peptide generation via proteasome degradation to be mostly a stochastic
process. In vitro experiments on the SIINFEKL peptide, derived from ovalbumin,
demonstrated that the proteasome cleaves through this peptide 90% of the
time.80 This indicates that the proteasome is generally more destructive to
peptides than productive. Therefore it could be possible that the low
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concentration of bortezomib may reduce the probability of PR1 peptide
destruction in the cells that end up presenting PR1. However, these hypotheses
would need to be further validated through experimentation. It is clear that a
greater understanding of the effects of proteasome inhibition on crosspresentation are needed. Specifically, further studies into the mechanistic activity
of both 8F4 antibody and bortezomib are necessary and warranted, especially in
the area of multiple myeloma where combination therapy is commonplace.

The other class of anti-myeloma drugs, IMiDs, does not appear to have
any adverse effects on antigen presentation. Our work demonstrated that
lenalidomide did not affect the expression of HLA-A2 nor PR1/HLA-A2
expression on the surface of multiple myeloma. While more consideration is
needed when potentially combining PR1-targeting immunotherapy with standard
of care therapies such as bortezomib, PR1 immunotherapies may be more
readily integrated and combined with IMiDs.

The ER appears to be the major site for PR1 loading onto HLA-A2 in
multiple myeloma. When treated with an ER to Golgi transport inhibitor, brefeldin
A, we observed a significant decrease in PR1/HLA-A2 surface expression on
multiple myeloma cells. This suggests that PR1 cross-presentation follows the
cytosolic pathway model for cross-presentation. Our work has also demonstrated
that TAP plays a prominent role in PR1 cross-presentation, as silencing TAP
resulted in decreased recognition of PR1/HLA-A2 by PR1-CTLs. These
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observations further support that PR1 cross-presentation follows the cytosolic
pathway model. However, we have not conducted the experiments to definitively
rule out the roles of the vacuolar or peptide-exchange models in PR1 crosspresentation. It is possible that PR1 can be cross-presented via all three
mechanisms at some level of efficiency-a consideration that could aid in
explaining the contradictory effects observed with bortezomib proteasome
inhibition. Others have reported mechanisms in DCs where the HLA-A2 restricted
peptide, gp100, is efficiently cross-presented via the vacuolar pathway in a TAPindependent manner.81 Interestingly, it was further demonstrated that the
vacuolar pathway for cross-presentation is not exclusively TAP-independent.82
While our data illustrate that the cytosolic pathway and the ER and TAP play a
prominent role in the cross-presentation of PR1 by multiple myeloma, it is
becoming clear that the models of cross-presentation are not mutually exclusive.
Cells may utilize a combination or multiple pathways for effective antigen crosspresentation.

Interestingly, our PR1 tetramer findings demonstrate that the TCR
repertoire of multiple myeloma patients contains TCRs that recognize PR1 after
allo- and auto-SCT. These data further support the feasibility of targeting PR1 in
multiple myeloma as there appears to be immunity against PR1 in these patients.
The frequency of PR1-CTL in multiple patients also suggests alternative avenues
for PR1-based immunotherapies. Natural PR1 immunity could potentially be
boosted further using PR1 peptide vaccines. In this study, we found PR1-CTL in
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the peripheral blood and bone marrow, suggesting that these PR1-CTL have the
capacity to infiltrate and home to the bone marrow tumor site. In agreement with
these observations, we also noted that the majority of PR1 dextramer positive T
cells aligned with the effector memory phenotype (CCR7-/CD45RA-). However,
the fate of these PR1-CTL remains unknown. Further experiments are needed to
assess their expansion potential and reactivity functions. Effector memory T
cells are characterized by their activation status, containing large quantities of
perforin and IFN-γ, and being poised to readily initiate effector functions upon
antigenic stimulation.83 It is tempting to speculate that the PR1-CTL we observed
could function as PR1 marrow-infiltrating lymphocytes (MILs) and could further
be expanded ex vivo and transferred using adoptive T cell therapy. Although, it is
important to note that adoptive T cell transfer of naïve or central memory T cell
subsets may be more ideal for a long-term anti-myeloma immunity.84

While our studies have demonstrated the feasibility of targeting PR1 in
multiple myeloma, it is important to recognize potential toxicity concerns. We
recognize that since PR1 is a self-antigen, there may be off target effects when
utilizing PR1-targeting immunotherapies. PMN and other non-malignant myeloid
cells endogenously express NE and P3 and would therefore theoretically express
PR1/HLA-A2 through normal antigen presentation. However, the level of
expression of PR1 by myeloid precursor cells in the bone marrow was shown to
be lower than the aberrant expression by leukemia.50 This would suggest a lower
density of 8F4 on healthy hematopoietic cells that may be insufficient to trigger
lysis of normal cells. Additionally, extensive preclinical studies and clinical trials in
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the setting of leukemia have illustrated safety and efficacy of PR1-targeting
immunotherapies despite PR1 originating from the normal self antigens NE and
P3.49,50,52,68

Additionally, the safety of targeting self-antigens such as PR1, have been
supported by the ability to target other tumor-associated self antigens, such as
Wilm’s Tumor-1 (WT1) and NY-ESO185,86 Similar to PR1, WT1 has HLA-A2
restricted epitopes and is aberrantly expressed in many solid tumor and
hematological malignancies, including AML.87 Importantly, WT1 has been
effectively targeted in AML using WT1-specific immunotherapies, including WT1
TCR-like monoclonal antibody, WT1 CAR-T cells, and WT1 peptide vaccine,
without off target toxicities.68,86,88-90 NY-ESO1 is another tumor-associated
antigen that has been characterized as an attractive immunotherapeutic target in
multiple myeloma. Despite its origins as a self-antigen, there has been interest in
developing NY-ESO1 immunotherapies, with success.91 The feasibility of
targeting other self-antigens indicates that targeting PR1 in multiple myeloma
may also be a practical strategy.

NE and P3 are primarily localized to the azurophilic granules in mature
granulocytes and PMN,92 sequestering them from endogenous antigen
presentation by the cell. Due to this siloing, the majority of NE and P3 are not
accessible for proteasomal degradation and subsequent antigen processing of
the PR1 peptide.50 Moreover, transcription of NE and P3 are reduced in pro-
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myelocytes and decreases over granulocyte maturation.93,94 This spatial and
temporal control over NE and P3 expression may result in low endogenous
antigen presentation of PR1 by mature granulocytes, which would reduce ontarget off-tumor binding of PR1-targeting immunotherapies. Importantly, targeting
PR1 has demonstrated clinical safety in the setting of leukemia. Qazilbash and
colleagues conducted a phase I/II clinical trial that not only demonstrated
tolerability and safety of PR1 peptide vaccine, but also showed vaccination
induced specific immunity that correlated with clinical response.49

It is not surprising that we noted some level of binding of 8F4 antibody to
HLA-A2 molecules alone. This observation is due to the fact that HLA-A2 is part
of the combined conformational PR1/HLA-A2 epitope that 8F4 antibody
recognizes. We have observed low background binding in the setting of leukemia
and lung cancer.40,41,43 Additionally, we did observe very low levels of
background binding in unpulsed U266 multiple myeloma (Figure 26). In previous
work from our group, fine epitope mapping revealed that 8F4 antibody has
contact residues with the helical domain of HLA-A2 molecules, which may help
provide an explanation for the observed background binding by 8F4 antibody.
However, binding experiments using ELISA with other high affinity HLA-A2
peptides (pp65 and WT1) wherein 8F4 antibody failed to recognize these other
peptide complexes, have demonstrated the specificity of 8F4 antibody to
PR1/HLA-A2.50
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Overall we have described a novel mechanism by which multiple myeloma
can express new tumor antigens by cross-presentation. These findings will allow
for new immunotherapies to be applied to treating this malignancy.
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Figure 32: Summary of PR1 cross-presentation by multiple myeloma

Figure 32: Summary of PR1 cross-presentation by multiple myeloma. In the
bone marrow, multiple myeloma cells take up NE and P3 from resident
polymorphonuclear cells (PMN). NE and P3 are then processed by the
proteasome and the PR1 peptide is loaded onto HLA-A2 molecules in a TAPdependent manner in the ER. PR1/HLA-A2 complexes are then expressed on
the multiple myeloma cell surface, rendering multiple myeloma susceptible to
PR1-targeting immunotherapies such as 8F4 antibody and PR1-CTL.
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Chapter 7: Future Directions

Our study has provided evidence that multiple myeloma is capable of taking
up exogenous antigens and cross-presenting novel peptides that can be targeted
by immunotherapy. However, this raises several new questions to be explored.
What is the mechanism by which NE and P3 are taken up by multiple myeloma?
What clinical impact does cross-presentation hold for future treatment of multiple
myeloma?

The mechanism of NE and P3 uptake in hematological malignancies remains
an important question. This is due in large part to the ubiquitous expression of
NE and P3 in inflamed tissues, including tumors. While our group has led the
investigation into the mechanism of NE uptake in solid tumors, we have yet to
explore this mechanism in multiple myeloma. Kerros and colleagues have
delineated a receptor-mediated mechanism for NE uptake in breast cancer. Their
studies, utilizing immunoprecipitation and mass spectrometry, identified that
neuropilin-1 (NRP1) is a receptor that is responsible for NE uptake in breast
cancer.44 Their hypotheses were guided by two important observations. NE
uptake by breast cancer was observed to be dose and time dependent and was
saturable after long co-cultures. Additionally, NE was observed to localize to the
early endosomal compartment at early time points, all of which suggested a
receptor-mediated mechanism.53 Interestingly, our multiple myeloma uptake
studies closely resemble the uptake kinetics seen breast cancer cells, suggesting
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that there may be a receptor responsible for NE uptake by multiple myeloma.
However, NRP1 expression is notably absent in U266 multiple myeloma cells
indicating there may be another receptor present and responsible. Similar
immunoprecipitation and mass spectrometry based approaches could be
employed to identify the receptor responsible for NE uptake in multiple myeloma.
These findings would be important in furthering our understanding of antigenand cross-presentation by cancer cells, specifically in the setting of multiple
myeloma. The mechanism of P3 uptake has yet to fully explored in solid or
hematological cancers but would be another area of interesting research.

The antigen presentation machinery were shown to play a critical role in PR1
cross-presentation by multiple myeloma. We specifically investigated the
essential contributions of the ER/Golgi, proteasome, and TAP. Our work also
illuminated a potentially integral role of calnexin for HLA maturation in multiple
myeloma patients. We observed that a lower isoform of calnexin is expressed in
multiple myeloma patient cells and was correlated to reduced expression of HLA.
The reduced HLA expression was also observed to resemble the immature,
double-band, phenotype of HLA molecules that were retained in the ER.66 We
speculate that the lower calnexin isoform may function as a dominant negative
chaperone, outcompeting canonical calnexin, and preventing proper HLA folding
and binding to the PLC. This could be possible as there are three described
isoforms of calnexin that are produced through alternative mRNA splicing, as
notated in the UniProt protein database. The shortest variant of calnexin, isoform
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3, is missing amino acids 1-108 at the N-terminus. This truncation in isoform 3
could potentially affect the binding of calnexin to HLA through its globular,
glycan-binding domain, which is formed in part by the N-terminus.95 Additionally,
canonical length calnexin has been shown to retain HLA in the ER in TAPdeficient cells.96,97 Together with our studies, these observations suggest a
possible mechanism of calnexin mediated HLA retention in the ER and improper
HLA expression. However, more experimentation would be necessary to
characterize this mechanism and test these hypotheses. Future investigations
that explore the role of calnexin would be warranted, as from a teleological
perspective, this could be novel immune escape mechanism utilized by multiple
myeloma to further avoid CD8+ T cell detection and destruction.

The work presented here illustrates strong preclinical evidence for PR1
targeting immunotherapies for the treatment of multiple myeloma. Our
investigations specifically have shown that PR1-CTL and 8F4 antibody can
effectively reduce the myeloma burden and prolongs survival in xenograft animal
models. Additionally, our data highlights that 8F4 antibody therapy could be
combined with other standard of care treatments already used for treating
multiple myeloma patients such as lenalidomide and even possibly bortezomib.
However, further mechanistic studies are necessary to explore how these
combinatorial therapies may interact. Multiple myeloma patients commonly
receive granulocyte colony stimulating factor (G-CSF) to mobilize bone marrow
cells in preparation for auto-SCT. This process increases the expression of NE
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and P3 in the bone marrow and would therefore increase the availability of
sources for PR1 for cross-presentation.48,98 8F4 antibody could be readily
integrated at this stage, as a purging strategy, where multiple myeloma cells
would be most likely to cross-present PR1. 8F4 would also be highly applicable
to multiple myeloma patients with large disease burdens. Our pre-clinical studies
in mice where high disease burdens were significantly reduced with 8F4 antibody
therapy alone support these speculations. In addition to 8F4 antibody, PR1 has
been targeted using other modalities such as PR1 peptide vaccine and PR1-CAR
T cell therapy.49,55 Each of these different strategies could be applied to multiple
myeloma patients in different stages depending on the disease burden. For
example, PR1 peptide vaccine could be highly valuable as a consolidation
therapy post SCT or in the setting of collecting stem cells for transplant.
Additionally, CAR T cell therapy may find attractive synergy when combined with
checkpoint blockage.

Finally, to our knowledge, our work is the first to document that multiple
myeloma can cross-present an exogenous antigen, PR1, and can be targeted for
destruction using PR1-specific immunotherapies. This important finding opens up
a new realm of possible exogenous tumor associated antigens to be targeted in
multiple myeloma. Currently, the exploration for new cancer antigens, via
surveying the HLA ligandome, has erupted in the field of cancer medicine.71,99-101
However, our studies suggest that future antigen discovery experiments should
be conducted with cross-presentation in mind. Importantly, multiple myeloma has
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a low mutational burden compared to many of cancers.102 Considering that much
of antigen discovery has focused on neoantigens derived from mutated antigens
in both solid and hematological cancers, cross-presented peptides may be even
of higher importance in the setting of multiple myeloma where neoantigens may
not be as abundant as they are in other cancers. With personalized, individualbased therapy approaches becoming more of a reality,103,104 it will be even more
vital to consider how tumor cells present antigens.
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